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ABSTRACT
Persistent Oral Dyskinesias Iduced by Long-Term Haloperidol
Treatment Is Dissociated from Changes in Neostriatal
Bb>x and mRNA Content for Dopamine Da Receptors
by
Nuyou Huang
Due to the presumed associations of dopamine (DA)
receptor supersensitivity phenomena in both long-term
neuroleptic-treated tardive dyskinetic rats and neonatal 6hydroxydopamine (n6-0HDA)-lesioned rats, we studied the
influence of haloperidol on n6-OHDA-lesioned rats. At 3
days after birth rats received 6-OHDA-HBr (200 pig, bilateral
intracerebroventricularly; desipramine pretreatment, 20
mg/kg, i.p., 1 h) or vehicle. Two months later haloperidol
(1.5/kg/day x 2 days/week for 4 weeks, then 1.5 mg/kg/day,
every day for 10 months) was added to the drinking water.
Spontaneous oral activity of intact and nS-OHDA-lesioned
rats receiving haloperidol was reached and maintained at
significantly higher levels after 15 weeks of haloperidol
treatment. Haloperidol treatment produced greater oral
activity in n6-0HDA-lesioned rats as compared to intact
rats. At 11 months there were 35.8±4.9 vs 18.4±2.1 oral
movements in lesioned vs. intact rats receiving haloperidol.
This high level of spontaneous oral activity was not
attenuated by scopolamine and persisted in the lesioned rats
for at least 8 months after haloperidol withdrawal. Reverse
transcription polymerase chain reaction (RT-PCR) analysis of
alternatively-spliced isoforms of DA Da (Das and DaL)
receptors showed that DaL receptor mRNA levels of intact and
n6-OHDA-lesioned rats receiving haloperidol were
significantly elevated after 11 months of treatment and
returned to normal level 8 months after haloperidol
withdrawal. Similarly, the B*** for [3H] raclopride binding
to striatal homogenates was significantly increased in
intact and n6-0HDA lesioned rats receiving chronic
haloperidol. The Baax was at the control level after 8
months of haloperidol cessation. Das and 5-HTac receptor
mRNA levels were not altered by chronic haloperidol
treatment. The effects of assorted receptor-specific drugs
on oral activity were tested in our rats to study possible
mechanisms underlying the regulation of oral activity. The
findings of this study demonstrate that alterations at mRNA
and receptor levels of DA Da receptors are not critical for
maintaining persisting enhanced oral dyskinesias after long
term haloperidol treatment.
The long-lasting stable high
frequency of oral dyskinesias after haloperidol withdrawal
in these rats provides a means for testing agents that have
the potential to attenuate dyskinetic oral activity.
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Introduction

A. Central Dopamine Systems
Soon after the discovery of dopa decarboxylase enzymes
dopamine (DA) was identified as an intermediate in the
catecholamine synthesis pathway (Holtz et al., 1938).

In

1958 Carlsson and colleagues correctly proposed that DA
serves not only as a precursor of norepinephrine (NE) and
epinephrine (Epi) synthesis, but also as a neurotransmitter
in the brain (Carlsson et al., 1958).

There are far more DA

neurons than other catecholamine neurons in brain.

In terms

of the functional and anatomical organization, brain DA
systems can be classified as follows (Ganong, 1991,* Cooper
et al., 1991):
1 . The nigros tria tal dopaminergi c sys tern.*
DA cell bodies in the pars compacta of the substantia
nigra have axonal projections to basal ganglia in the
forebrain.

This extrapyramidal system has a major role in

regulating fine motor control.

The destructive loss of

nigral DA cells is correlated with a Parkinsonian syndrome.
2. The mesocortical dopaminergic system;
DA cell bodies in the ventral tegmental nucleus and
portions of the substantia nigra have axonal projections to
the limbic cortex. This system is considered to have a major
role in modulating thinking patterns and motivational state.
An imbalance of this system might be expressed as neurosis,
1

psychosis or schizophrenic state.
3, The tuheroinfundibular, incertohypothalamic, and
periventricular dopaminergic system;
Cell bodies of these three DA systems arise in or near
the hypothalamus and have short axonal projects to adjacent
brain regions, like the median eminence.

DA, released by

the tuberoinfundibular system, is the primary inhibitory
regulator of prolactin hormone release.

Other pituitary

hormones, including growth hormone, are influenced in part
by this DA system.
B . Dopamine Receptors and Behavior
DA receptors can be broadly classified into presynaptic
receptors (autoreceptors) and postsynaptic receptors.
Autoreceptors exist in most portions of DA cells such as the
soma, dendrites and nerve terminals.

Somatodendritic

autoreceptors regulate the firing rate of dopamine neurons
while terminal autoreceptors regulate the synthesis and
release of DA.

Therefore, autoreceptors can be defined as

synthesis-modulating, release-modulating and impulsemodulating autoreceptors in terms of their functional roles
(Cooper et al., 1991).

Postsynaptic DA receptors are

located postsynaptically to DA-releasing cell types.
The cDNAs of five DA receptor subtypes have been cloned
(Sibley et al., 1993; Gingrich and Caron, 1993; Zhang et
al., 1994).

The most popular classification of DA receptors

divides these five

receptor subtypes into Dx-like receptors

and Da-like receptors, on the basis of their biochemical
characteristics (Kebabian and Caine, 1979; Breese and
Creese, 1986; Seeman and Van Tol, 1994).
1, Dx-like receptors:
D^like receptors include Dx and D( subtypes.

When DA

binds to these receptors on postsynaptic neurons, there is
generally an increased intracellular synthesis of cyclic
adenosine monophosphate (cAMP) (Kebabian and Caine, 1979) .
2. D3-like receptors:
Dj, Da and D4 DA receptor subtypes fall into the Da-like
receptor category.

DA stimulation of these receptors

generally inhibits the activity of adenylate cyclase and
thereby reduces synthesis of intracellular levels of cAMP
(Kebabian and Caine, 1979) . Da receptors trigger signal
transduction pathways in many ways that are different from
that of Dt receptors.

In addition to their ability to

inhibit the activity of adenylate cyclase, cloned Da
receptors are able to stimulate phosphatidylinositol
turnover (Vallar et al., 1990), regulate K* and Ca3* channel
activity (Vallar et al., 1990;

Castellano et al., 1993) and

increase arachidonic acid release (Kanterman et al., 1991).
Autoreceptors can be classified into D,-like receptors in
terms of their biochemical and pharmacological
characteristics (Cooper, 1991).
Behavioral studies of dopaminergic systems was
initiated by Randrup and co-workers about 30 years ago

(Randrup et al., 1965).

The availability of relative

specific DA receptor ligands enabled functional studies of
the behavioral roles of DA receptor subtypes.

The overall

body of evidence suggests that DA Dt and D, receptors are
associated directly or indirectly with the mediation of
behavior responses (Andersen and Nielsen, 1966).

Central DA

systems play important roles in the regulation of motor
activities and mental functions (Ganong, 1991).

Motor

behaviors are usually considered to be under the control of
nigrostriatal DA pathway (Ungerstedt and Arbuthnott, 1970;
Ungerstedt, 1971) while mesolimbic and mesocortical DA
pathways regulate emotional and reward behaviors (Creese and
Iversen, 1973).

The dysfunctions of nigrostriatal and

mesocortical dopaminergic systems are linked to Parkinson's
disease and schizophrenia, respectively (Ganong, 1991;
Stevens, 1973).

DA agonists and antagonists are effective

agents in the treatment of these two types of neuronal
disorders.
C. Neonatal 6-hydroxydopamine (n6-0HDA) Treatment and
Supersensitivity of Central DA Systems

Removal of neuronal input is one of the important means
to study the functions of a particular neuronal system
(Kostrzewa and Jacobowitz, 1974).

The remarkable discovery

of Tranzer and Thoenen revealed that 6-OHDA, an isomer of
NE, selectively destroyed peripheral catecholaminecontaining neurons (Tranzer and Thoenen, 1967; Tranzer and

Thoenen, 1968).

When adrenergic neurons are protected by

desipramine pretreatment,

6-OHDA produces a selective

lesion o£ the DA system (Breese and Traylor, 1972).

Upon

stimulated by DA agonists, behavioral responses, such as
stereotyped behavior, locomotor and oral activities, are
greatly enhanced in n6-OHDA-lesioned rats.

This evidence

indicates that central dopaminergic systems are
supersensitized by n6-0HDA treatment

(Breese et al., 1984;

1985a,1985b; 1987; Kostrzewa and Hamdi, 1991; Kostrzewa and
Gong, 1991; Hamdi and Kostrzewa,1991, Gong et al., 1992,
Kostrzewa and Neely, 1993).
D. Neonatal 6-OHDA Treatment and Number of DA Neurons in Rat
Brain
Using an antibody to tyrosine hydroxylase (T-OH) Berger
et al. (1985) found that the number of T-OH immunoreactive
(THIR) cell bodies in pars compacta of the substantia nigra
were too numerous to count in intact rats.. They estimated
>4000 THIR cells in this nucleus.

In contrast, in n6-0HDA-

lesioned rats (150 fig 6-OHDA, base) there were only 12 to
110 THIR remaining cells in this nucleus (mean of 63 cells).
Similarly, unilateral intrastriatal injection of 6-OHDA (8
M9) on postnatal day 2 (P2) caused a significant retrograde
degeneration of THIR neurons in the substantia nigra of the
lesioned side at F9 and P22 (Cabothe et al., 1991).
Bilateral intracerebroventricular (icv) injection of 6OHDA (100 fig each side) resulted in a marked loss of THIR

neurons in mesencephalon. The loss of THIR neurons was more
severe in the substantia nigra pars compacta and in the
ventral A9 cell group of the A9 complex while the A10 region
and the lateral cell group of the A9 complex were less
severe by affected (Luthman et al., 1990a). Yokoyama et al.
(1993) reported that intracisternal injection of 6-OHDA (67
fig) on PI

induced degeneration of THIR neurons.

The

decrease of immunoreactive intensity and the appearance of
dot-like

THIR processes, was first found in the substantia

nigra 12 h after the injection of 6-OHDA.

The

immunoreactive neurons at the substantia nigra were
marginally detected 96 h after 6-OHDA.

In contrast to the

DA neurons at the substantia nigra, there was no detectable
degeneration of THIR neurons or terminals in the
hypothalamic arcuate nucleus and in the median eminence at
least 96 h after the injection of 6-OHDA. In addition, when
n6-OHDA-lesioned rat brain tissues were analyzed at 2-5
months after birth, it was found that intracisternal
injection of 6-OHDA (67 fig) on PI or unilateral
intraparenchymal injection of 6-OHDA (8 fig on P3) produced
almost complete depletion of THIR neurons in the substantia
nigra and striatum.

Less extensive changes of THIR neurons

were found in the ventral tegmental nucleus, arcuate nucleus
(A12), zona incerta (A13), periventricular area (A14) and
posterior hypothalamic area (All). In order to exclude the
possibility that the difference in regional 6-OHDA

7
concentrations by intracisternal injection may

contribute

to the difference in the sensitivity of substantia nigra and
hypothalamic THIR neurons to 6-OHDA toxicity, the same dose
of 6-OHDA was injected at PI by different routes (intra
lateral or third ventricles), Similarly, the degeneration of
THIR neurons and fibers was found only in the substantia
nigra and caudate putamen, not in the hypothalamus.
Therefore, it is unlikely that the difference in
sensitivity to 6-OHDA is due to a difference in the regional
concentration of 6-OHDA (Yokoyama et al., 1993).
Differences in uptake-accumulation and/or intraneuronal
factors that interfere with the auto-oxidation reaction of
6-OHDA may be responsible for differences in sensitivity

to

6-OHDA (Jonsson, 1983). There are 2 to 3 times more high
affinity dopamine uptake sites in nigrostriatal DA neurons
than in tuberoinfundibular DA neurons (Annunziato et al.,
1980) .
E. Neonatal 6-OHDA Treatment and DA Uptake Sites
Using quantitative autoradiography (QAR) with
[3H]mazindol as the ligand for high-affinity DA uptake sites
(a DA terminal density marker), it was found that the
developmental pattern for DA uptake sites was parallel to
that of DA receptors.

That is, patch compartments developed

at an early stage in life and this was followed by
maturation of the matrix compartment (Rao et al., 1991).
Bilateral intrastriatal injection of 6-OHDA (4, 8, or 20 fig

each side) at PO or PI resulted in an extensive alteration
in the number of DA uptake sites {Neal and Joyce* 1991,
1992; Neal-Beliveau and Joyce, 1993). n6-0HDA-lesions caused
a dose-dependent patchy loss of high affinity DA binding
sites (Neal-Beliveau and Joyce, 1993), There was an overall
22-75% reduction of [3H]mazinol binding sites in the
striatum of the nS-OHDA-lesioned rats at low dose (4 /ig each
side) and intermediate dose (8 fig each side), whereas the
high dose (20 fig each side) caused almost complete loss of
[JH]mazindol binding sites (Neal-Beliveau and Joyce, 1993).
The most extensive loss of [’Hlmazindol binding sites was in
the dorsomedial quadrant of the left striatum which showed a
43% loss of binding sites. Accumbens septi (NAS) was less
affected, there being a loss of only 15% of binding sites
(Neal and Joyce, 1992).
F. Neonatal 6-OHDA treatment and

DA receptor mRNA

In situ hybridization and autoradiographic studies
showed that

DA Da receptors are detectable at PI in the

caudate-putamen. Dt receptors density reaches adult levels
at P16. The development and maturation of Da receptors
occurs later,

DA D3 receptor binding can not be observed

until P3 in the striatum and not until P7 in the globus
pallidus and substantia nigra.

The density of D, receptors

approaches adult level between P16 and P30 (Rao et al.,
1991).

Using slot bolt and in situ hybridization as tools,

it was reported that D, mRNA was detectable in striatum on

the day of birth, then increased gradually and reach peak
levels at P16.

The different peak time for slot blot and in

situ hybridization

may be due to the difference of Da mRNA

expression at the subpopulations of the neurons. Similar to
the DA receptor binding characteristics, the distribution of
Da mRNA also showed a lateral to medial gradient in the
striatum.

Ontogenetic development of Da receptor mRNA was

reported to be correlated to the expression of Da receptor
(Chen and Weiss, 1991).

In another study using polymerase

chain reaction (PCR) techniques, it was reported that whole
rat brain

Da receptor (DSJW44 and DaA41s receptors) mRNA was

measurable at P14 and day P17 respectively and then
increased to the adult level {Mack et al., 1991).

In this

study mRNA was not detected prior to P14. The possible of
the expression of Da receptor mRNA prior to P14 can not be
excluded. Therefore, there are dramatic ontogenetic changes
in striatal Dt and Da receptor densities and their mRNA
levels. Dt and Da receptor densities and mRNA levels
increase after birth until P15 to P30, then decline slightly
(Chen and Weiss, 1991; Mack et al., 1991; Xu et al., 1992).
The daily treatments of intact rats with SKF 38393
[(±)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol
hydrochloride, 3.0 mg/kg/day, i.p.], for the first 28 days
from birth did not alter the expression of Dt mRNA in rat
striatum when analyzed at 11 weeks of age.

Similar

ontogenetic SKF 38393 treatment of neonatal 6-OHDA-lesioned

rats (67 fig in each lateral ventricle at P3) significantly
reduced rat striatal DA Dt mRNA level. However, the level of
DA Di mRNA was restored by 4 weekly SKF 38393 treatments
(3.0 mg/kg/day, i.p) during the 6th through the 9th weeks
after birth (Gong et al., 1994}.

It has been reported that

the presence of dopaminergic neurons is required for the
normal expression of Dt receptors (Saleh and Kostrzewa,
1989).

Also the loss of DA D1 and Da receptor sites has

been found after a neonatal 6-OHDA-lesion (Deskin et al.,
1981; Gelbard et al., 1990). These series of studies suggest
that endogenous DA might be important for the development of
DA receptors (Gelbard et al., 1990; Saleh and Kostrzewa,
1989).
In other investigations the ontogenetic development of
central DA systems was impaired either by icv injection of
6-OHDA (134 ^g) on P3,

daily injection of the Da receptor

antagonist SCH 21390 [R-(+)-7-chloro-8-hydroxy-3-methyl-lphenyl-2,3,4,5-tetrahydro-lH-3-benzazepine hydrochloride,
0.25 mg/kg/day, i.p.) from P4 to P20,

or the combined

treatments with 6-OHDA and SCH 23390.

When analyzed at P21,

it was found that none of these three treatments was able to
alter the level of DlA receptor mRNA in both caudate-putamen
and the nucleus accumbens. There was also no alteration in
Da receptor binding ([3HJSCH 23390) (Duncan et al., 1993).
Similarly, striatal Da mRNA levels in the brain of 16 and 32
day old rats was not altered by n6-OHDA (bilateral icv, 67

fig each side) treatment at P3 and P6 (Chen and Weiss* 1991) .
Striatal Da mRNA was found significantly increased (15%)
after high dose of bilateral icv 6-OHDA treatment (150 (tg
each side) at P3 as assessed at 60 days after birth.

The

increase of D3 mRNA was more obvious in the lateral than in
the medial striatum.

Lower dose of 6-OHDA (67 fig) did not

cause change in D3 mRNA level (Soghomonian, 1993).

These

findings do not support the view that dopaminergic input is
a critical factor for postnatal ontogenetic expression of DA
mRNA* although it is possible that central DA systems may be
involved in striatal DA receptor development prior to n6OHDA treatment. More work is needed to clarify the
relationship between ontogenetic dopaminergic input and the
expressions of DA receptor mRNAs and their proteins.
Q. Neonatal 6-OHDA treatment and DA receptors
Autoradiography studies with specific ligands have
revealed the ontogenetic developmental characteristics of DA
receptors (Rao et al., 1991; Cabeche et al., 1991; Murrin
and Zeng, 1989). Using ['HJSCH 23390 as a ligand, clear
heterogeneous patchy binding was found in rat striatum at
PI, most obviously in the rostrocaudal extension of the
lateral two-thirds of the striatum. At P3 and P4, the patchy
distribution of [*H]SCH 23390 binding was observed in the
whole latero-medial and rostro-caudal extension of the
striatum. The distribution of Dt patches was parallel to
that of the THIR staining. Beginning from P9, there was

dissociation between the relative distribution of [3H]SCH
23390 binding and THIR staining.

Patchy binding was

observed only in the ventral part, not the dorsal part of
the striatum at this age.

However, THIR fibers were present

to a greater extent in the dorsal vs. ventral striatum.

By

22 days after birth [JH]SCH 23390 binding and THIR staining
were found homogeneously distributed in the whole striatum.
(Caboche et al., 1991).

This suggests that there is a

separate organization of patchy and matrix compartments
during development. The density of Dt receptor was 16% of
the adult level at PI and reached 38% at P10.

Afterwards,

there was a dramatic elevation of Dt density between P10 to
P16. In contrast, the development characteristics of D2
receptors is different from that of Dt receptors. D,
receptors were not detectable until P3 and reached the adult
level between P16 to P30 (Rao et al., 1991). These
differences in the ontogenetic development of these DA
receptor subtypes may give rise to their difference of
vulnerability to 6-OHDA toxicity.

Therefore, the time at

which neonatal lesion is performed may be critical for
changes in DA receptor subtypes.
The effects of n6-OHDA depletion on central DA systems
and DA receptors are highly controversial. It was found
that DA receptors were unaltered (Breese et al., 1987; Dewar
et al., 1990; Hamdi and Kostrzewa, 1991; Kostrzewa and
Hamdi, 1991; Caboche et al., 1991;), decreased {Duncan et
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al., 1987; Dewar and reader, 1989; Neal and Joyce, 1992;
Neal-Beliveau and Joyce, 1993; Radja et al., 1993) or
increased (Broaddus and Nennett, 1990) in adult rats after
the depletion of central DA systems with n6-OHDA treatment.
In a study involving nS-OHDA treatment {67 fig,
intracisternally) of rats at P3, autoradiography with the DA
Di ligand [3H]SCH 23390 revealed no change from control, of
[JH]SCH 23390 binding in dorsolateral striatum, dorsomedial
striatum, ventrolateral striatum, ventromedial striatum and
nucleus accumbens (Simson et al., 1992).

When rats were

observed at P9 and P22, Caboche et al. (1991) demonstrated
that unilateral intrastriatal injection of 6-OHDA (8 fig) at
P2 did not cause any alteration in the [3H] SCH binding
pattern and density at lesioned and unlesioned sides of
ventral, dorsal and whole striatum.

This treatment resulted

in a significant decrease of THIR fibers in the striatum and
a retrograde degeneration of THIR neurons in the substantia
nigra.

Because of the dissociations between THIR fiber

distributions and [JH]SCH 23390 binding patterns, the
authors suggested that ontogenic development of Dt receptors
may not be depend upon the presynaptic DA elements (Caboche
et al., 1991).
In contrast to the above results, bilateral
intrastriatal injection of 6-OHDA (4, 8, or 20 fig each side)
at P0, PI or P2 produced significant loss of [3H]SCH 23390
binding of Dx receptors in the striatum. This patchy

reduction of Dt receptor binding was not dose-dependant. The
loss of D3 binding was preferential to the dorsomedial
caudate-putamen (CPu) and the patchy compartment.

In

contrast to the changes in Dx receptor subtypes, this
treatment did not cause a significant alteration in striatal
Da receptor number.

Although the reduction of D3 receptor

binding density was greater in the medial CPu than that in
the central and lateral CPu regions, the normal lateral to
medial gradient D3 binding characteristic in the striatum
was not altered by intrastriatal n6-0HDA treatment.
absence of change in D, receptors may due to the

The

fact that

Da receptors are not present in the striatum at the time of
6-OHDA treatment (Neal and Joyce, 1992; Neal-Beliveau and
Joyce, 1993).

Radja and associates (1993) reported that

bilateral icv injection of 6-OHDA (50 (ig each side) at P3
caused significant changes in both Dx and D3 receptors as
determined by autoradiography.

Dt receptor binding (['HJSCH

23390) in the rostral striatum was significantly decreased
whereas there was no marked alteration in the caudal
striatum.

DA D3 receptor binding

significantly increased

([*H] raclopride) was

(23-27%) in all parts of the caudal

striatum and most parts (dorsolateral, dorsomedial and
ventrolateral) of rostral striatum (except ventromedian
quadrants of the rostral striatum). In the substantia
nigra, the density of D3 binding was dramatically (80%)
elevated.

In situ hybridization study revealed that there

»
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was no alteration in the amount of D, receptor mRNA in the
striatum of n6-0HDA-lesioned rats vs control rats.
Using tJH] raclopride as a ligand, Dewar et al (1990)
found that n6-0HDA treatment was not associated with an
alteration in Bn>x or Kd for DA Da receptors in the rostral
striatum at 15 days and 1 month of age.
months the

was increased by 25%.

However, at 3

In caudal striatum the

Bn„x and Kd of [3H] raclopride binding did not change at these
intervals after n6-OHDA treatment.

Broaddus and Bennett

(1990) applied 3 different protocols for the n6-0HDA lesion
to obtain selective damage of DA systems: (1). Bilateral
intrastriatal (i.s.) injection of 6-OHDA (20 /ig) at P2 to
cause selective destruction of the 'patches'; (2). Four
weekly (1 to 4 weeks) injections (i.s.) of 6-OHDA (20 fig) to
destroy DA terminals in both patchy and matrix systems; (3).
Intracisternal injection of 6-OHDA (120 fig) at P3 to cause
extensive damage .of midbrain DA neurons.

It was found that

all these treatment protocols resulted in an increase (1540%) in the BnaK of SCH 23390 binding in the striatal
homogenates. The first and second protocols also led to an
increase of Kd for SCH 23390 binding to Dx receptors. This
may implicate a depletion supersensitivity of Dt receptors.
However, these lesion protocols decreased Da receptor
density (B..^) in the striatal homogenates, using [JH] {-)
sulpiride as ligand.

These results indicate that the

development of Da receptors is probably regulated by DA
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innervations (Broaddus and Bennett, 1990).
Receptor binding studies indicate that n6-OHDA
treatment supersensitizes DA Dx receptors without altering
Dx receptor density (Bmjut) and affinity (Kd) (Hamdi and
Kostrzewa, 1991; Luthman et al., 1990b; Duncan et al.,
1967).

It is known that DA Dl receptors have high and low

affinity states of agonist binding (Leff et al., 1985;
Seeman et al., 1985).

No change in the distribution of D1

receptor high and low agonist binding sites was found in n6OHDA-lesioned rats (Gong et al., 1994).
The mechanisms underlying the changes in DA receptors
after n6-OHDA are still unclear. It was proposed that the
depletion of endogenous DA may contribute to the DA receptor
changes after n6-0HDA treatment (Gelbard et al., 1990). It
was found that in intact rats, there was a negative
correlation between the densities of DA receptor binding
and the levels of DA in forebrain tissue.

This' inverse

correlation was eliminated by daily administration of
exogenous DA (SKF 38393).

Similarly, the changes of D,

receptor binding induced by n6-0HDA treatment was restored
by SKF 38393.

These findings indicate that there is an

important role of endogenous DA in regulating Dt receptor
development (Gelbard et al., 1990).

In adult animals,

transplantation of fetal mesencephalic DA neurons did not
reverse the loss of DA receptors (Blunt et al., 1992).
developmental stage at which the

central DA system

is

The
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depleted is an important determinant of the changes in DA
receptors by nG-OHDA treatment (Neal and Joyce., 1992; NealBeliveau and Joyce., 1993).

Furthermore, DA receptor

'

supersensitization in n6-OHDA-lesioned rats can not be
simply explained by changes in either DA receptor binding
parameters or the expressions of DA receptor mRNAs.

It has

been suggested that an imbalance among DA, 5-HT and other
neurotransmitter systems underlies the phenomenon of DA
receptor supersensitivity (Gong et al., 1994; Kostrzewa and
Neely, 1993, Kostrzewa, 1995).
H. Anatomy of Central Serotonin Pathways
Serotonin (5-HT) was isolated and synthesized and its
chemical structure was defined in late 40's and early 50's
(Hamlin and Fisher, 1951; Rapport, 1949; Rapport et al.,
1948).

The significant abundance of 5-HT in various regions

of the central nervous system (CNS) suggests that it is a
major CNS transmitter (Amin et al., 1954),

The discovery of

the involvement of 5-HT in the major psychoses (Jacobs,
1984) led to a great deal of interest in this
neurotransmitter.

Although the numbers of 5-HT cells in the

CNS constitute only about 1/1,000,000 of all CNS neurons,
the influence and regulation of 5-HT systems on their target
sites seem to be much greater than their numbers (Jacobs and
Azmitia, 1992)
The 5-HT neurons can be defined into superior and
inferior groups that are located in the brain stem around
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the midline {Jacobs and Azmitia, 1992).

Projections of 5-HT

axons from cell bodies in the dorsal and medial raphe
located in the midbrain innervate various regions of the
brain such as substantia nigra, striatum, mesolimbic system,
hippocampus, hypothalamus and forebrain region (Meltzer and
Nash, 1991).
5-HT projections to substantia nigra and striatum are
originate from the rostral potion of the dorsal raphe (Imai
et al., 1986; Molliver, 1987).

Afferent 5-HT fibers from

both dorsal and medial raphe innervate mesolimbic regions
such as the ventral tegmentum (Simon et al., 1979; Parent et
al., 1981).

Medial raphe 5-HT neurons project to the

hippocampus (Moore and Halaris, 1975).

5-HT fibers arising

from both the dorsal and medial raphe pass through the
hypothalamus and innervate forebrain regions (Meltzer and
Nash, 1991).
I. Serotonin Receptors and their Functional Roles
The latest classification of Serotonin Club Receptor
Nomenclature Committee defined 5-HT receptors into seven
classes base on three fundamental properties: operational
(drug-related), transductional (receptor-coupling) and
structural (primary amino acid sequence) characteristics
(Humphrey et al., 1993; Martin and Humphrey, 1994).

The

characteristics of each 5-HT receptor class are outlined as
follows:
1. The 5-HT1 receptor
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Five 5-HT receptor subtypes are recognized as 5-HTi
receptors.

These include 5-HT1A, 5-HT1B, 5-HT10, 5-HT1B and 5-

HTlP. They all have seven transmembrane (TM) domains and
are linked to the inhibition of adenylate cyclase (Martin
and Humphrey* 1994) .
a. 5-HT1A receptors
This subtype of 5-HT receptors is located primarily in
the limbic system, with a lesser extent in dorsal and median
raphe nuclei. These regions regulate mood, anxiety,
temperature, feeding and locomotion.

5-HTlx receptors are

important for the action of antipsychotic drugs (Meltzer and
Nash, 1991; Martin and humphrey, 1994).
b. 5-HT1B receptors and 5-HT1D receptors
5-HT1B receptors are
rodents. These receptors

unique in rats and some other
are not present in humans.

The

exact physiological functions of 5-HT1B and 5-HT1D receptors
are not clear, because of the lack of specific ligands.
They may function either as autoreceptors or regulate the
release of acetylcholine, glutaminate or other
neurotransmitters..

Substantia nigra and basal ganglia are

two areas with the highest densities of 5-HT1B and 5-HT1D
receptors (Engel et al., 1986, Maura and Raiteri, 1966).
c. 5-HTia and 5-HTlp receptors
The distribution of

5-HT1B receptors is similar to that

of5-HT1D receptors in the CNS (Leonhardt

et al., 1969).

However, unique distributions of 5-HTlp receptors, which
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include the pyramidal cells of the cortex and, the dorsal
raphe and the hippocampus, have been revealed (Amiaiky at
al., 1992; Martin and humphrey, 1994).

The physiological

roles of these two receptor subtypes are yet to be
determined.

There are still no selective ligands for these

receptor subtypes.
2. 5-HT3 receptor
5-HTa receptors consist of three subtypes, namely 5HTaA, S-HTaB and 5-HTac receptors.

They all have seven TM and

are coupled to phospholipase C and increased production of
IPj (Hoyer et al., 1994,; Martin and Humphrey, 1994).
a. 5-HTiA and 5-HTaa receptors
5-HTja receptors exist primarily in cortex, and to a
lesser extent in hippocampus and caudate nuclei (Hoyer et
al., 1986).

These receptor subtypes are known to have

regulating roles for motor activity and sleep (Sharpley et
al,, 1990).

5-HTaa receptors are found only in peripheral

tissues, such as the stomach fundus (Kursar et al., 1992).
b. 5-HTjC receptors
5-HTac receptors distribute with highest density in
choroid plexus and to a lesser extent in the limbic system,
basal ganglia, hypothalamus and hippocampus (Pazos et al.,
1987: Julius et al., 1988; Molineaus et al., 1989).

5-HTac

receptors have been proposed as having a regulating role for
oral activity (Gong et al., 1992; Kostrzewa and Gong, 1991),
locomotion, eating and anxiety (Kennett and Curzon, 1988;
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Kennett et al., 1989; Lucki, 1992).
3. 5-HT3 receptor
5-HT, receptors are structurally and functionally
distinct from all other 5-HT receptors.

In fact, these 5-HT

receptors are ligand-gated cation channels {Martin and
Humphrey, 1994).

In the CNS 5-HT, receptors are found in

the area postrema, the nucleus tractus solitarius, the
dorso-vagal complex and the trigeminal nucleus caudalis
(Waeber et al., 1988; Kilpatrick et al., 1990).

5-HT,

receptors modulate the release of other neurotransmitters
such as DA (Blandina et at., 1988) and r-aminobutyric acid
(GABA) (Alhaider et al., 1991).
4. 5-HT4 receptors
The structure of 5-HT4 receptors is currently unknown.
In the CNS, activation of 5-HT4 receptors in the hippocampus
elevates the formation of cAMP (Dumuis et al., 1988) and
decrease K* conductance (Andrade and Chaput, 1991).

It was

shown that 5-HT4 receptors are also localized in the
striatum, substantia nigra and olfactory tubercle of rats
and guinea-pigs.

However, the functional role of 5-HT4

receptors remains to be determined (Grossman et al., 1993).
5. Other 5-HT receptors
5-HT,, 5-HT,, and 5-HT7 receptors are the newest numbers
of the 5-HT receptor family.

Their genes were cloned

recently (Plassat et al., 1993; Monsma et al., 1993; Ruat et
al., 1993).

It has been proposed that 5-HT, receptors
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feature seven TM and are coupled to G-protein.
messenger system is unknown.

Their second

Very little is known about the

functional roles of 5-HT,, 5-HT, and 5-HT, receptors (Martin
and Humphrey, 1994).
J. Neonatal 6-OHDA Treatment and 5-HT Fiber Sprouting in Rat
Striatum
The 5-HT content of the striatum of rats treated
neonatally with 6-OHDA (100-200 fig; desipramine
pretreatment) has been found to be elevated by 50 to >100%
(Breese et al., 1964; Stachowiak et al., 1964).

A 20%

reduction in size of the striatum could not account for the
elevation in striatal 5-HT content in n6-0HDA-treated rats.
Further study revealed that 5-HT content of caudal striatum
remained unchanged whereas 5-HT content of rostral striatum
was elevated as much as 4 to 5-fold (Stachowiak et al. ,
1984; Dewar et al. , 1990).

The elevation in 5-HT content

of rostral striatum was accompanied by a proportionate
increase in the [3H]5-HT accumulation by striatal
homogenates (Stachowiak et al. , 1984).

These findings

indicated that the loss of DA innervation of the striatum
did not influence the 5-HT fiber innervation of caudal
striatum, which has a 5-HT content and 5-HT fiber input that
is 3 to 6 times that of rostral striatum.

However, the loss

of DA input to the striatum seemed to induce heterotypic
sprouting and hyperinnervation of rostral striatum by 5-HT
fibers.
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Using an antibody to 5-HT, it was shown that n6-0HDA
treatment was associated with a several-fold increase in the
number of 5-HT-immunoreactive (IR) fibers in rostral
striatum.

The fine and highly varicose fibers increased in

number by only a slight amount in caudal striatum {Snyder et
al., 1986; Luthman et al., 1987).
The change in 5-HT content in rostral striatum of n6OHDA rats was not accompanied by a change in 5-HT content of
the olfactory tubercle or septum (Stachowiak et al., 1984),
nor frontal cortex, occipital cortex, mesencephalon, raphe
nucleus or cerebellum (Luthman et al., 1987).

A 30%

increase in 5-HT was measured in the cingulate cortex, 3
months after n6-0HDA (Dewar et al., 1990).

Numbers of 5-

HTIR fibers in the basal forebrain, septum, cortex and
substantia nigra were also not altered (Snyder et al.,
1986).
K. Neonatal 6-OHDA treatment and 5-HT Receptors

In the striatum of intact and n6-OHDA-lesioned rats 5HT1A receptors are not present.

The low numbers of 5-HT1B

and 5-HT,A receptors were increased in the rostral striatum
of n6-OHDA-lesioned rats by 30% and 60%, respectively.

5-

HTlnonAB(3C receptors, which were most abundant in the striatum
of intact rats, were increased by 35% in rostral striatum of
n6-OHDA-lesioned rats (Radja et al. 1993).
In the caudal striatum, as in rostral striatum, 5-HT1B
and 5-HTlnonAB|3C receptors were increased by 30 to 35%, while
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5-HTaA receptors were not altered in numbers in n6-OHDAlesioned rats. Because numbers of 5-HTJA receptors and
numbers of 5-HT fibers are increased in rostral striatum of
n6-0HDA rats, it was suggested that 5-HT fiber proliferation
accounted for the change in 5-HTax receptor number (Radja et
al., 1993).
There was no change in the number of 5-HT1A receptors
in lateral septum, CA1 area, dentate gyrus and dorsal raphe
of nfi-OHDA-lesioned rats.

Similarly, there was no change in

the number of 5-HTaA receptors in claustrum and nucleus
accumbens of n-6-OHDA-lesioned rats.

It was suggested that

the cumulative upregulation of assorted 5-HT receptor
subtypes would effectively enhance actions of synaptic 5-HT,
even if the synaptic content of 5-HT was the same as in
intact rats (Radja et al., 1993).
L. Tardive Dyskinesia (TD)

TD is a syndrome of involuntary, repetitive and
purposeless hyperkinetic abnormal movements that occur
during or after chronic neuroleptic treatment.

Orofacial

regions and sometimes the limbs and trunk are most commonly
involved (Waddington, 1990,* Jeste and Caligiuri, 1993).
TD was first described by Schonecker (1957), five years
after the introduction of the neuroleptic chlorpromazine as
a treatment of psychosis.

The term "tardive dyskinesia" was

first used by Faurbye et al. in 1964 to describe this latedeveloping movement disorder (Faurbye et al., 1964).

Long-
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term use of neuroleptics is the major risk factor for TD
(Jeste and Caligiuri, 1993).
The reported prevalence of TD varies from 0.5 to 100%.
This wide range may be due to the differences in risk
factors, treatment characteristics and diagnostic criteria.
Conservatively, it is usually agreed that the prevalence of
TD is between 15 to 20%.

In high risk patients, such as the

elderly, the prevalence is as much as 70% {Casey, 1987).
M. Risk Factors for TD
1. Age and Gender
Age is the primary risk factor for TD, with there being
a positive correlation between the prevalence and severity
of TD with age (Smith and Baldessarini, 1980; Jeste and
Wyatt, 1982b). Age-related degeneration of the
nigrostriatal DA system may be one underlying basis of this
phenomenon (Jeste and Caligiuri, 1993).

A higher incidence

with greater severity of TD occurs in females (Casey, 1987) .
2. Psychiatric diagnosis
Neuroleptic-treated schizophrenic patients are less
likely to develop TD than neuroleptic-treated mood disorder
patients (Casey and Keepers, 1988; Mukherjee et al., 1986).
3. Organic brain damage
Since TD is the consequence of treatment of patients
with mental disorders, it is possible that CNS damage may be
a risk factor for TD (Yassa et al., 1984).

There is some

disagreement with this view (Gold et al., 1991).

In future
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studies it would be valuable to assess the relationship
between TD and brain damage.
4. Other factors
There is reportedly a higher incidence of TD in people
that smoke or have diabetes.

Asians have the lowest

incidence of TD, indicating that ethnicity or genetic
differences may represent risk factors for TD (Jeste and
Caligiuri, 1993; Yassa et al., 1987).
N. Tardive Dyskinesia and Central DA Neurons
Up until recently the most widely-accepted hypothesis
on the origin of TD was that TD was related-to development
of DA receptor supersensitivity.

This was based mainly on

the knowledge that movements disorders are a consequence of
DA receptor block in the nigrostrial system.

It is

extremely difficult to conduct postmortem studies on TD
patients, since this is a neuroleptic-induced disorder and
the therapy is often sufficiently variable so that it is
difficult to reasonably group patients into subsets.

Also,

residual neuroleptics in these patients would still exert a
block of brain DA receptors.

Therefore, most evidence on

the pathophysiology of TD are derived from animal models
(Casey, 1987).
In studies on intact and/or n6-0HDA-lesioned rats it
has been found that oral activity is induced by DA Dt
agonists (SKF 38393 and A77636) and DA Da antagonists
(sulpiride, spiperone and haloperidol). Therefore, it

appears that an imbalance of D1/D2 receptor activity plays a
prominent role in the induction of oral activity
(Rosengarten et al., 1983; Gong et al., 1992; Huang and*
Kostrzewa, 1994b). In studies on rats treated long-term
with neuroleptics, an increase in the Bmax and Kd for DA
receptors has been reported {Chiu et al., 1981; Rupniak et
al., 1984).

These associated behavioral and biochemical

indices are supportive of the hypothesis that an overactive
DA system may contribute to the pathophysiology of TD
(Klawans, 1973; Chiu et al., 1981; Rupniak et al., 1984;
Jeste and Caligiuri, 1993).
In other subsequent studies, there have been findings
that conflict with those just described.

Waddington et al.

(1983), using direct measurements on postmortem brain from
humans with TD, found that there was a dissociation between
behavioral and DA receptor changes.

Blin et al. (1989),

using positron emission tomography on brains of humans with
TD, also found a discrepancy between oral dyskinesias and
changes in DA receptors.

Recently, attention has been

focused on a multi-neurotransmitter theory of TD, in which
there is a seeming imbalance between regulation by different
kinds of neurons (Casey, 1987; Waddington, 1990; Jeste and
Caligiuri, 1993} .
O, Regulation of Oral Activity in Rats by Multiple
Neurochemical Systems

It is well-established that DA neuronal systems have an
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integral role in regulating oral activity in rats
(Rosengarten et al., 1983; Gong et al., 1992; Kostrzewa and
Gong, 1991; Kostrzewa and Hamdi, 1991; Huang and Kostrzewa,
1994a).

Serotoninergic (Stewart et al., 1989; Gong et al.,

1992; Kostrzewa et al., 1992), cholinergic (Rupniak et al.,
1983, 1985a; Salamone et al., 1990), GABAergic (Gunne et
al., 1984; Morelli et al., 1985; Lloyd et al., 1985) and
peptidergic (Liminga, 1993) neurons are also involved in
regulating oral activity.
Acute treatment with the cholinergic agonist
pilocarpine significantly increases oral activity in rats.
This effect is produced when pilocarpine is administered
directly into the ventrolateral striatum via a cannula
implant.

Also, when pilocarpine or the cholinesterase

inhibitor physostigmine is administered in drinking water
for three weeks, there is an increased incidence of oral
activity (Rupniak et al., 1985b).

The effect of pilocarpine

and physostigmine in this last study was attenuated by the
muscarinic receptor antagonist, scopolamine (Salamone et
al., 1990).

The acute treatment of chronic haloperidol-

treated rats with pilocarpine or physostigmine results in an
increased number of oral movements in rats (Rupniak, 1983).
It is yet to be determined, however, whether cholinergicinduced oral activity represents an oral dystonia or an oral
dyskinesia.
It is possible that GABA agonists have a therapeutic

effect on dyskinesia, since GABA agonists interact with DA
systems to alter behavioral responses (stereotyped and
dyskinetic movements) induced by lesions or DA agonists
(Gunne et al., 1984; Morelli et al., 1985).

It was reported

that the GABA agonists muscimol and progabide have
beneficial effects on TD patients (Lloyd et al., 1985;
Morelli et al., 1985; Tamminga et al., 1979).

In animal

studies, a microinfusion of the GABA antagonist bicuculline
and GABA-depleting agent isoniazid bilaterally in the
substantia nigra greatly increased oral activity of rats
(Gunne et al., 1988).

GABA agonists attenuated oral

activities of cats, monkeys and rats (Lloyd et al., 1985;
Mithani et al., 1987).

These findings suggest that an

impaired GABA system may be involved in abnormal oral
activities (Mithani et al., 1987).
Central (intranigral) or peripheral administration of .
receptor agonists [1,3-di-o-tolylguanidine (DTG) and {+)pentazocine] or the . receptor antagonist naloxone resulted
in increased oral activity in rats.

This may be related to

a release of DA in the striatum (Patrick et al., 1993;
Cancela et al., 1988).

It is also known that the

intranigral infusion of the neurokinin NK1 agonist substance
P and NKj agonist neurokinin A produce dose-related
increases in purposeless oral activity in rats.

These

findings are compatible with the view that central
neuropeptides are involved in the regulation of oral
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activity (Liminga, 1993).
Extensive studies have been conducted to explore the
effects of DA 5-HT and cholinergic systems in regulating
oral activity in neonatal 6-OHDA-lesioned rats.

In n6-OHDA-

lesioned rats, there were enhanced oral activity responses
to the DA Dt agonist SKF 38393, the 5-HTa agonist mchlorophenylpiperazine (m-CPP) and cholinergic agonist
pilocarpine (Kostrzewa and Gong, 1991; Gong and Kostrzewa,
1992; Gong et al., 1992; Kostrzewa and Neely, 1993).

These

findings indicate that there is co-sensitization of DA, 5-HT
and cholinergic systems in n6-OHDA-lesioned rats (Kostrzewa,
1995).

Of the several 5-HT agonists that were tested in

these rats, only the 5-HTaAiac agonist m-CPP induced oral
activity.

The 5-HT1A agonist (±) -8-

hydroxydipropylaminotetralin (8-OH-DPAT) and 5-HT1B agonist
7-trifluoromethyl-4(4-ethyl-l-piperazinyl)-pyrrolo[l,2r
alquinoxaline] (CGS 12066B) did not increase the incidence
of oral activity.

Furthermore, the enhanced oral response

to m-CPP was attenuated by the 5-HTaA)JC receptor antagonist
mianserin, but not by the 5-HT1AtlB antagonist pindolol, 5HTaA antagonist ketanserin or 5-HTa antagonist MDL-72222 (3tropanyl-3,5-dichlorobenzoate). These findings indicate
that m-CPP-induced oral activity is mediated by 5-HTac
receptors and not the other 5-HT receptor subtypes (Gong et
al., 1992) .
In other studies on n6-0HDA-lesioned rats it was
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reported that the DA Dt receptor antagonist SCH 23390 did
not attenuate m-CPP-induced oral activity, but that the 5-HT
receptor antagonist mianserin attenuated oral activity
induced by the DA

agonist SKF 38393.

This indicates that

DA agonist-induced oral activity is mediated by 5-HTac
receptors (Gong et al., 1992).

In a later study it was

found that the muscarinic receptor antagonist scopolamine
effectively blocked the oral activity response to both SKF
38393 and m-CPP, but that SCH 23390 and mianserin did not
block the response to pilocarpine.

This finding indicates

that oral activity induced by DA and 5-HT systems are
mediated by cholinergic systems.

Therefore, these series of

studies indicate that DA neurons are acting via 5-HT neurons
which are acting via cholinergic neurons (Kostrzewa and
Neely, 1993) .
P. Rationale

The introduction of neuroleptics into clinical practice
in 1952 was a milestone in the treatment of psychiatric
disorders.

However, the beneficial effects of these drugs

were soon found to be counterbalanced by the appearance of
the serious syndrome known as tardive dyskinesia (TD). The
underlying basis of this adverse effect is still not known.
An earlier theory on the origin of TD was assumed to be
related to the development of DA receptor supersensitivity
(Klawans and Hitri, 1978; Chiu et al., 1981).

Today the

multi-neurotransmitter theory, based on the involvement of
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many neurochemical systems (Waddington* 1990; Caligiuri*
1993)* seems to be more in vogue.
critically reviewed the literature.

Waddington (1990) has
Nonetheless* there*has

been a steady increase in the incidence of TD by about 1%
per year during the past 20 years (Casey, 1987; Jeste and
Caligiuri, 1993) .
Animal models that mimic the pathophysiology of human
TD are useful for studying putative mechanisms associated
with spontaneous oral activity and in studying potentially
useful drugs for TD. Non-human primates (Gunne et al.,
1984; Kovacic and Domino, 1984) and rodent models of TD
(Ellison and See, 1989; Waddington, 1990} have been used.
The most common animal model is chronic neuroleptic (usually
haloperidol)-treated rats.
There is still no single animal model which reproduces
the exact phenomenology of TD, particularly the
characteristic oral movement found in TD patients.

This may

be related to the fact that neuroleptics are usually
administered to psychotics, who are known to have an altered
disturbance in the CNS.

In contrast, the animals receiving

the neuroleptic are normal healthy rodents (Waddington,
1990).
In rats in which the neostriatal DA innervation has
been destroyed early in postnatal ontogeny by 6-OHDA, the
incidence of oral activity is greatly increased by DA
agonists (Kostrzewa and Hamdi* 1991; Kostrzewa and Gong*
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1991) and 5-HT agonists (Gong et al., 1992).

Rats lesioned

neonatally with 6-OHDA have been proposed as a better model
for TD (Gong et al., 1992; Huang and Kostrzewa, 1994b).
In order to test this hypothesis the following study
was performed.

Haloperidol was added to the drinking water

of intact and neonatal 6-OHDA-lesioned rats for nearly 1
year, while spontaneous and agonist-induced oral activity
was observed at one or two week intervals.

The objective

was to determine whether:
a.

persistent oral dyskinesias might be induced in
haloperidol-treated 6-OHDA-lesioned rats,

b.

mRNA levels of DA D, and 5-HTJC receptors might be
altered to different extents in intact and 6-0HDAlesioned haloperidol-treated rats,

c.

DA Dj receptor number might be altered by
haloperidol treatment of intact and 6-OHDAlesioned rats and

d.

receptor-specific compounds might attenuate
spontaneous oral activity in treated rats.

This study was expected to lead to a better
understanding of the pathophysiology of TD, particularly of
the roles of DA and other neurotransmitter systems in
regulating oral activity.

More significantly, there was the

potential for inducing long-lived spontaneous oral
dyskinetic activity'in rats, so that putative drugs for TD
could be reasonably tested for their ability to attenuate
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TD.

Chapter 2
Materials and Methods

A. Animal Treatment
1 . Animal
Time-pregnant Sprague-Dawley albino rats were purchased
from Charles River Laboratories (Research Triangle, NC)
approximately 1 week before delivery and housed singly in
clear Perspex cages in a room with constant temperature
(21±1<,C) and 12 h light-dark cycle (lights on at 07:00) .
Animals had free access to food and water.
birth was considered as postnatal day 0.
was recorded within 12 hr.

The date of
The time of birth

Litters were reassigned at

birth, so that each reconstituted litter consisted of about
equal number of pups from 10 different litters, for a
maximum of 10 pups per litter.
2. 6-OHDA Treatment
At 3 days after birth all rat pups were pretreated with
desipramine hydrochloride (20 mg/kg i.p., base form; Sigma
Chemical Co., St. Louis, MO, USA), 1 hr before bilateral
intracerebroventricular (icv) administration of 6-OHDA.

The

desipramine was intended to block NE transporters and
protect NE-containing neurons from 6-OHDA toxicity, thereby
increasing the selectivity of 6-OHDA for DA-containing
neurons.

6-OHDA HBr (100 fig, salt form, on each side;

Research Biochemicals Inc., Natick, MA, USA) was delivered
35
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via a microliter syringe equipped with a 26-gauge needle
having a polyethylene sleeve up to 2 mm from the tip of the
needle.

The injection was positioned 1.5 mm anterior to

lambda and 2 mm lateral to the sagittal plane.

The needle

was left in place for about 30 seconds after 5 pLl of 6-OHDA
HBr solutions or 0.1% saline-ascorbic acid vehicle was
injected into the lateral ventricle.

This procedure has

been described in detail {Kostrzewa and Gong, 1991).

Rats

were weaned at 28 days and group housed in wire cages.

Only

males were used in this study.
3. Haloperidol Treatment
Starting 2 months after birth about half the rats in
the 6-OHDA and vehicle groups received haloperidol (1.5
mg/kg/day) via drinking water, for 2 consecutive days a week
for 4 weeks.

Starting in the fifth week haloperidol was

administered on a continuous schedule (1.5 mg/kg/day) for 10
months.

Thus, the study consisted of four groups: (1) non-

lesioned rats with tap water as drinking water, (2) nonlesioned rats with haloperidol in drinking water, {3} 6OHDA-lesioned rats with tap water as drinking water, and {4}
6-OHDA-lesioned rats with haloperidol in drinking water.
The dose of haloperidol in this study reputedly produces
plasma levels of haloperidol that correspond to that of
people treated long-term with haloperidol (Tamminga et al.,
1990).

Rats were weighed once a week to adjust the dose of

haloperidol.
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4. Observation of Oral Activity
»

Spontaneous oral activity was observed one week before
instituting haloperidol treatment, then every 1 or 2 weeks
until the end of the study.

A variety of receptor-specific

drugs for different neurotransmitter systems were tested for
their effect on oral activity, during and after the phase of
haloperidol treatment.

These included drugs selective for

DA, serotonin, cholinergic, GABAergic and glutamatergic
systems.

Also, oral activity dose-effect curves for the DA

Di agonist SKF38393 and 5-HT, agonist m-CPP were constructed
for all groups of rats at 12, 36 and 38 weeks after
haloperidol treatment.
months of treatment.

Haloperidol was withdrawn after 11
Eight or nine days after withdrawing

haloperidol all rats were killed, except for 9 of the 6OHDA-lesioned group that had received haloperidol for the
past ll months.

Oral activity in these rats continued to be

observed for the following 8 months.
Oral activity determinations were performed in a wellventilated and well-lighted room.

Rats were placed

individually in clear plastic cages (48 X 26 X 36 cm) with
steel grid floors

and acclimated for at least 30 min.

Agonists or saline vehicle were administered ip to each rat
(1 mg/kg) 10 min before observation.

Antagonists or vehicle

were administered ip 1 hour before observation.

All

observation sessions were conducted with 9 rats per group
except when deaths reduced the pool size in 6-OHDA-lesioned

haloperidol-withdrawn rats. Numbers of oral movements were
counted in each rat by an experienced observer, for l min
every 10 min during a 60 min session.

Oral activity

represents spontaneous chewing {vacuous chewing) which is
not directed onto any physical material (Rupniak et al.,
1983; Waddington, 1990).

No distinction was made between

lateral and vertical jaw movements.

Directed oral activity

and food chewing sequences were not counted (Kostrzewa and
Gong, 1991; Huang and Kostrzewa, 1994a,b).
B. Neurochemical Analysis of Striatum
Eight or nine days after the withdrawal of haloperidol
rats were killed by decapitation.

Each brain was rapidly

removed and the striata were dissected free, frozen on dry
ice and stored at -70°C until the time of analysis.
Concentrations of DA, 5-HT and their metabolites in rat
striatum were determined by liquid chromatography with
electrochemical detection (LCEC). Each striatum was
sonicated in 1 ml of 0.10 M trichloroacetic acid containing
0.20 mg/ml of cysteine as a stabilizing agent.

5-

hydroxyindole carboxylic acid was used as internal standard.
Homogenates were centrifuged at 12,000 x g for 5 min and 30
Hi of each supernate was injected onto an Econosphere Cl8
analytical column (5 micron, 4.6 x 150 mm), having a mobile
phase of 0.10 M monochloroacetic acid, 1 mM EDTA, 220 mg/1
of Na octanesulfonic acid, 8% acetonitrile, pH 2.6, with a
flow rate of 1.3 ml/min and temperature of 40 °C (Gong et
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al., 1992).

A Hewlett-Packard HP1000 chromatography data

system was used to calculate peak heights and to determine
concentrations of DA, DOPAC, homovanillic acid (HVA), 5-HT,
5-hydroxyindoleacetic acid (5-HIAA) and noreprenophine (NE).
C. Assessment o£ Striatal D, Receptor Binding Parameters
A modification of the procedure of Dewar et al. (1989,
1990) was used to assess DA D, receptors in the striatum.
Rostral striata were homogenized with a Teflon on glass
mortar and pestle in 1:100 ice-cold 50 mM Tris buffer (pH
7.4).

This gentle homogenizing procedure was used to avoid

damage to receptors during this tissue preparation step
(Norman et al., 1989).

Homogenates were then centrifuged at

35,100 x g for 10 min at 4°C using a Beckman J2-21M
centrifuge and JA-20.1 rotor.

The supernatants were

discarded and the pellets were washed 4 times in the Tris
buffer by repeated pipettings, followed by centrifugation.
Final pellets were resuspended in 200 volumes of buffer.
Saturation curves were obtained in the following way.
Aliquots of homogenate (2 mg membrane in 400 fil) were added
to a series of incubation tubes with 10 different
concentrations (93-8245 pM) of the DA Da receptor antagonist
[JH]raclopride (specific activity: 82.4 Ci/mmol; Dupont).
The incubate consisted of Tris buffer (pH 7.4) containing
120 mM NaCl, 5 mM KC1 and 40 nM ketanserin (final cones.).
Samples were incubated in a final volume of 2.5 ml at 25 “C
for 60 min.

The incubation was terminated by rapidly
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filtering each sample under partial vacuum on Whatman GF/F
glass filters using a Millipore filtration unit.

Filters

were washed 3 time each with 5 ml ice-cold Tris-salt
solution, then placed into scintillation counting vials.
After drying overnight, 9 ml of scintillation solution was
added to each vial.

Tritium activity was determined in a

Beckman L5 9800 liquid scintillation spectrometer.
A GraphPad program (GraphPad Software Inc., San Diego,
CA) was used to construct the binding curves and calculate
receptor binding parameters,

and Kd, by fitting the data

to a double rectangular hyperbola equation [Y = A*X/(B+X) +
C*X/(D+X) + E*X]. Factor B in this equation was set as a
constant of zero since there was only one binding site for
Da receptors (Fig. l, sequential F test, P>0.05) (Dewar et
al., 1989, 1990).
D. Determination of mRNA levels for DJL, D„ and 5-HTac
receptors in the striatum

1. Messenger RNA Extraction and Purification
Total RNA was isolated and purified according to the
Ultraspec™-ll RNA Isolation System (Biotecx Laboratories,
Inc., Houston, TX). The rostral striatum of each rat was
homogenized in 1 ml of Ultraspec™ RNA reagent with a Tekmar
Tissumizer, setting of 5 for 25 sec.

Homogenates were

transferred to 1.5 ml polypropylene microcentrifuge tubes
and kept at 4°C for 5 min to allow dissociation of
nucleoprotein complexes.

Then, 0.2 ml of chloroform was

added to each isolation tube, followed by vigorous shaking
for IS seconds.

After 5 min on ice, homogenates were

centrifuged at 12,000 g for 15 min and the upper aqueous
phase which contained RNA was carefully transferred to a
fresh tube -- taking care not to disturb the interphase and
the lower organic phase.

Each tube was vortexed for 30

seconds after the addition of 0.5 volumes of isopropanol and
0.05 volumes of RNA Tack™ Resin.

Following a 1 min

centrifuge step with a table-top minicentrifuge,
supernatants were discarded and the pellets were washed with
2 x 1 ml of 75% ethanol by vortexing for 30 seconds and
spinning for l min.

The supernatants were discarded.

All

tubes were dried for 5 min in a vacuum centrifuge (VirTis
Co., Gardiner, NY) to remove traces of ethanol.

Pellets

containing RNA were eluted with diethyl pyrocarbonate
(DEPC)-treated water by vortexing for 30 seconds and then
spinning for 1 min.
transferred

Supernatants containing RNA were

to 0.6 ml

-70°C until used.

polypropylene tubes and stored at

Ten pi of aliquot RNA solution of each

sample was transferred into 490 pi of DEPC-treated water and
the optical densities of the samples at 260 nM and 280 nM
were obtained, to determine the concentration and purity of
the final RNA solutions.
2, Polymerase Chain Reaction (PCR)
mRNA determinations were performed with Perkin Elmer
GeneAmp RNA PCR Kit (Roche Molecular Systems, Inc.,
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Branchburg, NJ). One microgram of total RNA from each
sample was transcribed into single-stranded cDNA, using MuLV
reverse transcriptase and random hexamers and incubating
(42°C for IS min, 99°C and 5°C for 5 min each) in a Perkin
Elmer GeneAmp PCR system 9600 (Perkin Elmer, Roche Molecular
systems, Inc., Branchburg, NJ).
Two oligonucleotides (24-mer) flanking the alternative
spliced exon 6 of Da receptor cDNA were used for
amplification of the mRNA levels of two isoforms of D,
receptor, Datl and Das. The sequences of these two primers
(Martres et al., 1992; Della Vedova et al., 1992) are:
primer 1: 5'-TTCAGAGCCAACCTGAAGACACCA-3' (nucleotides 694717); primer 2: 5'GCTTTCTGCGGCTCATCGTCTTAA-3' (nucleotides
1067-1090) . The amplified fragment of Dat and Das receptors
were 397-bp and 310-bp respectively.
The levels of S-actin mRNA were also determined and
this served as the internal standard.

Two primers (Martres

et al., 1992) for fi-actin mRNA detection were 5'GATGGTGGGTATGGGTCAGAAGGA-3' (nucleotides 129-152) and 5'GCTCATTGCCGATAGTGATGACCT-3' (nucleotides 737-760).

The 5-

HTac receptor primers were 5'-ACACCGAGGAGGAACTGGCTAATAT-3'
and 5'-CTGGTAAACAGAACTGCCTCCGACTATC-3' which define a 601base-long DNA fragment.

Amplification was carried out for

35 cycles using a DNA thermal cycler (Perkin Elmer Cetus) at
the following condition: 95°C for 45 seconds, 58°C for 30
seconds and 72°C for 45 seconds.

The final products after

amplification were fractionated on 2% Metaphor highresolution agarose gel and stained with ethidium bromide.
Two bands of 397-bp and 310-bp for D3L and Dia receptors, a
band of 601-bp for 5-HTac receptors and a 632-bp band for fiactin were viewed and photographed with Polaroid positive
film (type 665) under an ultraviolet (UV) light source.

The

optical densities and areas of each band were analyzed by a
Bio Image Analysis System (Millipore Corporation Imaging
Systems, Ann Arbor, MI).
E. Data Analysis
1. Oral Activity:
Oral activity was expressed as the mean number of oral
movements in 6 min of a 60 min observation session ± S.E.M.
Statistically significant differences in oral activity
between groups was determined by one-way ANOVA, followed by
the post-ANOVA Newman-Keuls test.

In the case where

receptor-specific drugs were tested for their ability to
attenuate oral activities, the Student paired t-test was
used to determine significant differences within a group of
animals before and after administration of the drug.
2. Monoamine Determinations:
The mean tissue concentration of each monoamine and
metabolite (nmol/gram ± S.E.M.) was determined for all
groups of rats.

Differences between the groups for each of

these substances were determined by one-way ANOVA and a
post-ANOVA Newman-Keuls test.
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3. D3 Receptor Binding Parameters:
The double rectangular hyperbola equation of GraphPad,
using total membrane binding (DPM/fmol protein) for each
incubate concentration of [JH]raclopride (93-8245pM), was
used to construct specific- and nonspecific-binding curves
and to calculate values for

and Kd. It was determined

that there was only one binding site for [3H] raclopride, in
agreement with Dewar et al. {1989, 1990).

Differences in

and Kd between the groups were tested by one-way ANOVA,
followed by the post-ANOVA Newman-Kwuls test.
4, D3 and 5-HT3C Receptor mRNA levels.*
The relative levels of mRNA for each receptor were
expressed as a product of optical density and area of the
individual gel bands, following adjustment for internal
standard variations [i.e., dividing by levels of fi-actin
mRNA (optical density x area)]. The mean (± S.E.M.) content
of the mRNA levels of each group was then determined, and
these were compared among the different groups by one-way
ANOVA and the post-ANOVA Newman-Keuls test.
A P value equal to or less than 0.05

was considered to

be statistically significant in all of the statistical
analyses.

Chapter 3
Results
A. Before Haloperidol Withdrawal
l. Spontaneous Oral Activity
In intact rats receiving tap water, the incidence of
spontaneous oral activity was'low for the entire duration of
the experiment, remaining at less than 5 oral movements per
session (Fig.2;

Fig.3, 1st, 5th and 9th bars). The

spontaneous oral activity of n6-0HDA-lesioned rats that were
kept on tap water was slightly but not significantly higher
than that in the intact rat and remained stable for the
entire experiment duration (Fig. 2; Fig. 3, 2nd, 6th and
10th bars).
Starting in the 15th week of haloperidol treatment,
there was a significantly higher incidence of oral activity
in all haloperidol-treated rats (Fig.2 and Fig.3, P<0.01).
The high level of spontaneous oral activity remained stable
for the entire duration of haloperidol treatment (Fig.2).
In intact rats oral activity ranged from 14.4 to 20.4 oral
movements per session during the 11-month period of
haloperidol treatment (observations at 1- or 2-week
intervals). In the latest session there were approximately
18 oral movements, a 4-fold increase vs. intact rats on tap
water (Fig.2 and Fig.3, 1st, 3rd, 7th and 11th bars,
P<0.01).

A much greater effect was produced by haloperidol

administration to neonatal 6-OHDA-lesioned rats.
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In these
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rats spontaneous oral activity ranged from 27.6 to 41.6 oral
movements per sessions during the 11-month period of
haloperidol treatment.

In the latest session there were 36

oral movements, double that of intact rats which received
haloperidol {Fig.3, 7th and 8th, 11th and 12th bars PcO.Ol).
2. Supersensitization of DA and 5-HT systems
a. DA system
Dose-response curves for SKF 38393-induced oral
activity were constructed at 12 weeks and 36 weeks after the
administration of haloperidol (Fig.4 and Fig.S). As
expected, the 0.3 and 1.0 mg/kg doses of SKF 38393
significantly (P<0.01) increased oral activity in n6-OHDAlesioned rats during the 12th and 36th weeks of haloperidol
treatment.

The oral activity of n6-OHDA-lesioned rats

receiving haloperidol was also increased at the above 2 time
points with the same SKF 38393 doses. This indicates that DA
DL-mediated oral responses were enhanced in both* n6-OHDAlesioned and n6-OHDA-lesioned rats receiving haloperidol
treatment.
b. 5-HT system
The sensitivity of 5-HTac-mediated oral responses of
rats was also tested.

It recognized that m-CPP-induced oral

activity is mediated by 5-HTac receptors (Gong et al, 1992).
The dose-response curves for m-CPP-induced oral activity
were performed at 12th and 38th week of haloperidol
treatment.

m-CPP produced bell-shaped dose-response curves
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in n6-OHDA-lesioned rats, n6-0HDA-lesioned rats receiving
haloperidol and intact rats receiving haloperidol, the
optimal dose was 1.0 mg/kg (i.p.). Oral activities o£ these
three groups of rats were significantly increased by m-CPP
(Fig.6 and Fig.7}.

These results demonstrate that there is

enhanced 5-HTac-mediated oral activity in n6-OHDA rats and
in both groups of haloperidol-treated rats.
3. Effects of assorted receptor agonists and antagonists on
oral activity
a. DA Dt receptor antagonist
At a 1.0 mg/kg dose, the DA Da receptor antagonist SCH
23390 had no effect on the oral activity of both intact and
n6-0HDA-lesioned rats receiving tap water.

However, the

same SCH 23390 dose produced a significant reduction of oral
activity in both groups of rats that received haloperidol
(Fig. 9, P<0.05 for intact rats receiving haloperidol,
PcO.Ol for n6-OHDA-lesioned rats receiving haloperidol).
b. 5-HTac receptor antagonist
m-CPP and SKF 38393 produced significantly increased
oral activity in n6-0HDA-lesioned rats and both groups of
rats receiving haloperidol (Fig.9, 6th, 7th, 8th and 10th,
11th, 12th bars vs, 2nd, 3rd and 4th bars respectively,
PcO.Ol). The enhancement of oral activity induced by these
two agonists was attenuated by mianserin (1.0 mg/kg). This
finding indicates

that both SKF 38393 and m-CPP-induced

oral activity is mediated by a neural circuit with 5-HT
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receptors.
c. GABA receptor agonist and antagonist
Muscimol, a GABAa receptor agonist, at the dose of 3.0
mg/kg, significantly attenuated the number of oral movements
in n6-OHDA-lesioned rats receiving haloperidol (Fig.10,
P<0.05). This same dose of muscimol had no effect on oral
activity of intact rats receiving tap water or haloperidol;
and no effect on oral activity of n6-0HDA-lesioned rats
receiving tap water (Fig.10).

The GABA receptor antagonist

bicuculline (1.0 mg/kg) did not influence oral activity in
any of the groups (Fig.11).
d. Cholinergic receptor antagonist
The effect of the muscarinic receptor antagonist
scopolamine on oral activity of all rats was also tested
(Fig.12).

Analogous to SCH 23390, scopolamine (0.1 mg/kg)

had no effect on oral activity of intact and n6-0HDAlesioned rats receiving tap water. However, oral activity of
intact and n6-OHDA-lesioned rats receiving haloperidol was
significantly attenuated (Fig.12, P<0.05 and <0.01
respectively).
B. After Haloperidol Withdrawal
1. Spontaneous oral activity
In order to determine whether the haloperidol-induced
increased in spontaneous oral activity would persist in n6OHDA-lesioned rats, nine of the n6-OHDA-lesioned rats
receiving haloperidol continued to be observed after the

withdrawal of haloperidol. These rats were observed
periodically (once a week) for 8 months.

The high incidence

of oral activity of these rats remained stable (range of
28.5 to 38.5 oral movements per session) for the duration of
the experiment--8 months after the withdrawal of haloperidol
(Fig.13).

This finding indicates that chronic haloperidol

treatment produces a long-lived increase in spontaneous oral
activity of n6-0HDA-lesioned rats.

In order to assess the

long-term effects of haloperidol on DA and 5-HTac receptors,
it was necessary to take brain tissue within several days
after the cessation of haloperidol.

For that reason, and

based on the previously reported rapid decay of spontaneous
oral activity in intact rats after cessation of haloperidol
treatment (Tamminga et al., 1990; Mithani et al., 1987), it
was not able to observe this group after haloperidol
withdrawal.
2. .Effects of assorted receptor agonists and antagonists on
spontaneous oral activity
In order to determine the possible neuralmechanisms
underlying the regulation of oral activity, the effect of a
series of receptor-specific drugs was tested in the n6-OHDAlesioned rats during the haloperidol-withdrawal period,
a. DA receptor antagonists
SCH 23390 (1,0 mg/kg) had no effect on spontaneous oral
activity of n6-OHDA-lesioned rats after haloperidol
withdrawal.

The DA Da receptor antagonists spiperone (0.08

»
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mg/kg, i.p.) and metoclopramine (5.0 mg/kg, i.p.) also had
no effect on oral activity of these rats (Fig.14}.
b. 5-HT receptor antagonists
Ketanserin (5.0 mg/kg), pindolol (3.0 mg/kg) and
metoclopramine (5.0 mg/kg), respective 5-HTJA/ac, 5-HTlA/1B and
5-HTj receptor antagonists, had no effect on oral activity
of n6-OHDA-lesioned rats after haloperidol withdrawal
(Fig. 15) . These results suggest that 5-HTlA/lB, 5-HTaA and 5HTj receptors are not involved in regulating oral activity.
c. Drugs acting on other neuronal receptors
Drug acting on GABA receptors
Muscimol (3.0 mg/kg, i.p.), a GABA receptor agonist,
significantly attenuated oral activity in nG-OHDA-lesioned
rats after haloperidol withdrawal (P<0.01, Fig.IS).
Spontaneous oral activity of these rats was reduced from
28.1 ± 4.4 to 16.0 ± 3.9 movements per session after
muscimol.

These results support the view that GABA is one

of the neuronal systems involved in the regulation of oral
activity (Gunne et al., 1984; Morelli et al., 1985).
Drug acting on cholinergic receptors
Before withdrawing haloperidol, the muscarinic receptor
antagonist scopolamine (0.1 mg/kg, i.p.) significantly
attenuated spontaneous oral activity in both intact and n6OHDA-lesioned rats receiving haloperidol treatment (Fig.12).
However, after the withdrawal of haloperidol, the high
incidence of oral activity in n6-OHDA-lesioned rats was not

attenuated by scopolamine.

The spontaneous oral activity of

these rats was 30.5 ± 6.6 and 23.5 ± 3.0 movements per
session respectively before and after scopolamine (P>0.05,
Fig. 16).

The different effects of SCH 23390 and

scopolamine on spontaneous oral activity before and after
haloperidol withdrawal suggest that oral activity is
regulated differently in these two phases.

The failure of

scopolamine to inhibit oral activity after haloperidol
withdrawal indicates that the characteristics of oral
activity are analogous to the oral activity in TD patients
since it is usually agreed that scopolamine•alleviate the
early emergence of oral dystonia whereas cholinergic drug
improve the symptoms of tardive dyskinesia (Rupniak et al,
1984; Waddington, 1990).
Drugs acting on adrenergic receptors
Phenoxybenzamine (10.0 mg/kg) and phentolamine (2.0
mg/kg), two a-adrenoceptor antagonists, had no effect on
spontaneous oral activity of n6-OHDA-lesioned rats after
haloperidol withdrawal.

Similarly, the fi-adrenoceptor

antagonist propranolol (20.0 mg/kg) had no influence on
spontaneous oral activity of these rats (table 1).

This

implies that adrenergic systems do not have a prominent role
in regulating oral activity of these rats.
Drugs acting on histamine and adenosine receptors
Cyproheptadine (0.3 mg/kg) and ranitidine (5.0 kg/mg),
respective histaminergic

and Ha receptor antagonists, and
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theophylline (20 mg/kg), an adenosine receptor antagonist,
failed to attenuate spontaneous oral activity of the n6OHDA-lesioned rats after haloperidol withdrawal (table l') .
Drugs acting on NMDA. and opioid receptors
Ketamine (10.0 mg/kg), an NMDA receptor antagonist, and
naloxone (1.5 mg/kg and 5.0 mg/kg), an opioid mu receptor
antagonist, did not significantly alter oral activity in the
n6-0HDA-lesioned rats after haloperidol withdrawal.

At a

dose of 0.3 mg/kg, MK-801, an NMDA receptor antagonist,
significantly reduced the number of oral movement in these
rats (table l). However, treatment with MK-801 also caused
prominent salivation and sedation in these rats.
were virtually immobile after MK 801 treatment.

All rats
Therefore,

the reduction of oral activity by MK-801 in these rats may
be more reflective of general central nervous system
depression.
C. Changes of mRNA Levels of DA Da and 5-HTac Receptors
To correlate the functional changes with molecular
mechanisms,

the relative messenger RNA levels of DA DaL and

Daa receptors, two isoforms of Da receptors generated by
alternative splicing of the Da receptor gene, and the mRNA
levels of 5-HTac receptors were assessed by reverse
transcription polymerase chain reaction (RT-PCR) using fiactin as an internal standard.
1. Changes of mRNA levels of DA Dat and D3a receptors
As shown in figure 17, the striatal mRNA levels of Dat

receptors in intact and n6-0HDA-lesioned rats receiving
haloperidol were significantly increased as compared to the
mRNA levels of rats that were not treated with haloperidol
(Fig. 17, l .10±0.24 and 1.27±0.26 vs. 0.24±0.04 and
0.36±0.11, P<0.01).

However, 8 months after haloperidol

withdrawal, the mRNA levels of n6-OHDA-lesioned rats
returned to the level found in controls (Fig. 17, 0.44±0.13,
P>0.05) . The Dss mRNA levels of nfi-OHDA-lesioned rats,
regardless of whether haloperidol was administered was
slightly but not significantly increased when compared to
other treatment groups (Fig, 17).

This may indicate that

the changes of the D]L subtype of D, receptor is more closely
associated with the effect of long-term haloperidol
treatment.
2. Changes of mRNA levels of 5-HT2C receptors
Since 5-HTac receptors have an important role in
regulating spontaneous oral activity of rats (Gong et al.,
1992),

striatal 5-HTac mRNA levels were also assessed in

our rats.

In both groups (intact and n6-0HDA-lesioned rats)

that received haloperidol treatment, there was a slight but
not significant increase of 5-HTJC receptor mRNA level (Fig.
17, 13th and 14th bars vs 11th and 12th bars, P>0.05) .
Eight months after haloperidol withdrawal, the 5-HTac
receptor mRNA level was slightly reduced as compared to the
level at the time of haloperidol withdrawal(Fig. 17, 14th
bar vs 15th bar).
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D. Changes of DA D2 Receptor Binding Parameters
As revealed by [3H]raclopride binding to homogenates of
rat striatum,

chronic haloperidol treatment produced a

significant increase of Da receptor density (Bawt) in rostral
striatum of both intact and n6-0HDA-lesioned rats.

The Kd

was not significantly altered.

Eight months after

haloperidol withdrawal, the

of n6-0HDA-lesioned rats

returned to control levels (table 2).
E. Effects of n6-0HDA treatment on the levels of monoamines
and their metabolites in the striatum
1. DA, DOPAC and HVA levels
Neonatal 6-OHDA treatment produced a marked reduction
in the content of DA and DA metabolites in rat striatum.

DA

and HVA contents were reduced more than 96% in caudal
striatum of n6-OHDA-lesioned rats, regardless of haloperidol
treatment (table 3, PcO.Ol). DOPAC levels in the striata of
n6-0HDA-lesioned rats were also profoundly reduced (>89%).
Long-term haloperidol treatment produced a slight (about
12%) but significant reduction of DA, DOPAC and HVA levels
in the striatum of intact rats (table 3, P<0.05 or 0.01).
2. 5-HT, 5-HT metabolites and NE levels
Long-term haloperidol treatment per se had no effect on
striatal 5-HT content in intact and n6-0HDA-lesioned rats
However, there was a significant elevation of 5-HT content
in the striatum of n6-0HDA-lesioned rats (table 3, PcO.Ol).
The content of S-HIAA was significantly increased in the n6-

OHDA-lesioned rats vs. the intact rats, regardless of the
treatment of haloperidol (table 3).

Therefore, n6-0HDA

treatment significantly increased 5-HT and 5-HIAA contents
in rat striata, whereas haloperidol had little effect.
There was no changes in the content of NE in the striata of
the different treatment groups (table 3).

This indicates

that desipramine pretreatment effectively protected
noradrenergic neurons from nfi-OHDA destruction.
Accordingly, n6-0HDA produced a selective effect on the DA
system.
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Table 1

Effects of assorted agonists and antagonists on
spontaneous oral activity of rats during the 8 months
following termination of long-term haloperidol treatment
Number of Oral Movement
After Treatment
Test
Substances

Dose
(mg/kg)

cyproheptadine

0.3

27.9(5.0)

26.9(4.3)

Ketamine

10.0

27.9(2.8)

28.1(4.6)

Naloxone

1.5

37.7(7.4)

27.0(5.4)

Naloxone

5.0

31.7(3.8)

27.0(5.4)

Theophylline

20.0

32.4(4.2)

24.1(4.5)

Ranitidine

5.0

21.4(4.6)

23.9(4.3)

Phenoxybenzamine

10.0

13.7(2.1)

21.4(4.7)

Propranolol

20.0

24.7(6.2)

27,7(6.9)

Phentolamine

2.0

34.1(4.7)

30.1(5.4)

MK-801

0.3

5.4(2.4)

27.3(4.8)*

Morphine

1.0

33.4(3.5)

29.9(3.2)

Test
Substance

vehicle

Each value represents the mean(S.E.M.) number of vacuous
chewing movements of 6 to 9 rats. Rats were first observed
after i.p. or s.c. administration of vehicle, then after
administration of the test substances. Doses refer to salt
form of each substance.
*;P<0.01 when compared to vehicle treatment

Table 2
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Effects of n6-OHDA and chonic haloperidol treatment on
[3H]raclopride binding to rat striatum homogenates
Bn^fmol/mg protein)

Group

Ka(pM)

nVehicle + tap
water

203

(174-233)a

657

(492-817)

n6-OHDA+tap water

261

(219-303)b

809

(668-994)

nVehicle +
Haloperidol

339 (259-418)c

986

(776-1197)

n6-OHDA+
Haloperidol

350

(301-399)“

895

(822-966)

230

(172-287)*

704

(524-873)

n6-OHDA+
Haloperidol
(withdrawn)

Rats
recerved vehicle or6-OHDA
(100 pg
each side,
i.c.v., 20 mg/kg desipramine pretreatment, 1 hr)
3 days
after birth and haloperidol (1.5 mg/kg, via drinking
water) or tap water from 2 month for an 11 months period.
Rostral striata were removed 9 days or 8 months after
withdrawing haloperidol.
Saturable curves for striatal
homogenates were constructed, using binding data (n=5)
from
10
concentrations
of [3H]raclopride
(93pM
to
8250pM).
The
and
for 3H-raclopride binding was
determined with a computer program (GraphPad Software,
Inc.,
San Diego, C A ) . Data are expressed as mean (95%
confidence interval)
a vs.
e vs

c and a vs. d: PcO.Ol
c and e vs. d: P<0.05

Table 3
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Effects of neonatal 6-OHDA and chronic haloperidol
treatment on concentrations of monoamines and
their metabolites in the striatum
DOPAC

HVA

nVehicle* 8 52.8±5.7
tap water

7.6±0.9

4.010.2

n6-OHDA+ 9 1.6±0.5#
tap water

o.aio.i# O.llO.l# 5.310.2# 6.410.2# 1.010.1

Group

n

DA

5-HT
4.H0.2

nVehicle* 8 46.0±3.7* 5.3t0.5* 2.710.3* 4.310.2
Hal
n6-OHDA*
Hal

8 1,9±0.3#

0.6±0.1# 0.110.1# 4.810.3

5-HIAA
5.210.2

5.410.2

NE
l.llO.l

1.110.1

6.410.2# 1.210.1

Rats were treated at 3 days after birth with 6-OHDA HBr (100 ^g
each side, i.c.v., salt form; desipramine pretreatment, 1 hr) or
its vehicle, From 2 months after birth, haloperidol (Hal) was given
via drinking water (1.5 mg/kg/day, 2 days/week for 1 month, then
daily for 10 months). Strata were removed for assay 8 or 9 days
after the withdrawal of haloperidol. Values are mean nanomoles per
gram of tissue ± S.E.M.. Eight samples from each group was
detected.
*: p<0.05 and #:p<0.01 when compared to vehicle control group.
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Binding o f pH ]R aclopride to Rat Striatum.
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Fig.l. Representative saturation curves of [JH]raclopride
binding to rostral striatal homogenates of rats.
Aliquots
of striatal homogenates were added to a graded series of 10
concentrations of []H] raclopride (93-0245 pM) . Curves for
total, specific and nonspecific binding and the values for
Bmx and Kj were generated by fitting the data to a double
rectangular hyperbola equation [Y«A*X/(B+X)+C*X/(D+X)+E*X]
using a computer program (GraphPad Software Inc., San Diego,
CA) .
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E ffect of Haloperidol Treatment on S pontaneous Oral
Activity of In ta c t and Neonatal 6-OHDA-Lesioned R ats
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Fig.2. Time-course effects of chronic haloperidol treatment
on spontaneous oral activity of rats. Rats were treated at
3 days after birth with 6-OHDA HBr (200 /ig,salt form, half
in each lateral ventricle? desipramine pretreatment, 20
mg/kg, 1 hr) or vehicle. Haloperidol was added to the
drinking water starting at 2 months after birth (1.5
mg/kg/day x 2 days per week for 1 month; then daily for 10
months). Spontaneous oral activity was observed at 1- or 2week intervals during the 11 months of haloperidol
administration, in 1-h observation sessions (observation of
1 min every 10 min for 60 min). Each point represents the
mean number of spontaneous oral movements for each
observation. Starting from the 15th week after haloperidol
treatment, the spontaneous oral activity in both groups of
rats that received haloperidol was significantly higher than
before starting treatment (P<0.01). The high oral activity
in these rats persisted throughout the duration of the
experiment (n«9).
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E ffe c ts o f Prolonged Haloperidol Treatm ent on Oral. Activity
of I n ta c t and N eonatal 6-OHDA-Lesloned R ats
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Fig.3. Effect of long-term haloperidol treatment on oral
activity of rats. Rats received the treatments and
observations as described in fig.2. Bars represent the mean
number of spontaneous oral movements (±S.E.M.) one week
before starting haloperidol administration (-1 week, n»9), 6
months (6 months, n»9) or 11 months (11 months, n-9) after
haloperidol administration and Q months (19 months, n»7)
after discontinuing haloperidol.
*,**: Different labeled bars are significantly different
from each other, P<0.01.
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SKF 38393 D ose-Effect Curves at 12 Weeks of Haloperidol Treatment
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Fig.4. Doae-effect curves for SKF 38393-induced oral
activity of rats during the 12th week of haloperidol
administration. Oral activity was observed 10 min after
administration of SKF 38393 HC1 (abscissa). Each point
represents the mean number of oral movements (n»9)
(ordinate).
*: P<0.05 vs. the oral activity induced by vehicle in the
same group
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36 Weeks of Haloperidol Treatm ent
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Fig.5. Dose-effect curves for SKF 38393-induced oral
activity of rats during 36th week of haloperidol
administration. Legend ad in fig.4 (n«9)
*: P<0.01 vs. the oral activity induced by vehicle in the
same group
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a-CPP D ose-E ffect Curves at 12 Weeks of Haloperidol Treatment
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Fig.6. Dose-effect curves for m-CPP-induced oral activity
of rats during the 12th week of haloperidol treatment. Oral
activity was observed 10 min after administration of
mCPP 2HC1. Legend as in fig. 4 (n»9).
*: P<0.01 vs. the oral activity induced by vehicle in the
same group
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m-CPP D ose-Effect Curves at
3 8 Weeks of Haloperidol Treatment
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fig.7. Dose-effect curves for m-CPP-induced oral activity of
rats during the 38th week of haloperidol treatment. Legend
as in fig.4 (n«9).
*: P<0.01 vs. the oral activity induced by vehicle in the
same group
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E ffect of SCH 23390 on Spontaneous Oral Activity
of Rats During Haloperidol Treatment
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Fig.8. SCH 23390 attenuation of spontaneous oral activity
of rats during haloperidol treatment. Rats received 6-OHDA
and haloperidol treatment as described in fig. 2. Oral
activity was observed 10 min after vehicle administration
(saline, 1.0 ml/kg, i.p.) with or without SCH 23390 HCl (1.0
mg/kg, i.p., lh) pretreatment . Bars represent the mean (±
S.E.M,) number of oral movements (n»9).
bars with different labels were significantly
different from each other (P<0.01).
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E f f e c ts of Mianserin on Oral Activities*
Ind uced by SKF 3 8 3 9 3 and m-CPP
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Fig.9. Effect of mianserin on oral activity induced by SKF
38393 and m-CPP in rats. Rats received 6-OHDA and
haloperidol treatments as described in fig. 2. Oral
activity was observed 10 min after saline (1 ml/kg, i.p.),
SKF 38393 HCl (1.0 mg/kg, i.p.) or m-CPP 2HC1 (3.0 mg/kg,
i.p.) challenge with or without mianserin pretreatment (1
mg/kg, i.p., lh). Bars represent mean (± S.E.M.) number of
oral movement (n»9).
*: P<0.05 vs. oral activity of the same group pre-treated
with mianserin
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E ffect of Muscimol on Spontaneous Oral Activity
of Rats During Haloperidol Treatment
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Fig.10. Effect of muscimol on spontaneous oral activity of
rats during haloperidol treatment. Rats received 6-OHDA and
haloperidol treatments as described in fig. 2. Oral
activity was observed 10 min after vehicle administration
(saline, 1.0 ml/kg) with or without muscimol (3.0 mg/kg,
i.p., lh) pretreatment. Bars represent the mean (± S.E.M.)
number of oral movement (n=9).
**: P<0.01 vs. all other bars
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E ffect o f BicuculNne on S p o n tan e o u s Oral Activity
of R ats During Haloperidol Treatm ent
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Fig.11. Effect.of bicuculline on spontaneous oral activity
of rats during haloperidol treatment. Rats received 6-OHDA
and haloperidol treatments as described in fig. 2. Oral
activity was observed as described in fig. 10 (n»9).
Bicuculline did not attenuate the spontaneous oral activity
of rats (P>0.05).
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E ffect of Scopolamine on Spontaneous Oral Activity
of Rats During Haloperidol Treatment
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Pig.12. Effect of acopolamine on spontaneous oral activity
of rats. Rats received 6-OHDA and haloperidol treatments as
described in fig. 2. Oral activity was observed 10 min
after vehicle administration (saline, 1 ml/kg) with or
without scopolamine HCl (0.1 mg/kg, i.p., lh) pretreatment.
Bars represent mean (± S.E.M.) number of oral movement
(n«9) .
*,**: Different labeled bars are significantly different
from each other.
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S p o n t a n e o u s Oral Activity of Haloperidol-Withdrawn
N eo n a tal 6-O H D A -Lesioned R a t s
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Fig.13. Spontaneous oral activity in n6-OHDA-lesioned rats
after haloperidol withdrawal. The oral activity of n6-0HDAlesioned rats was observed 10 min after injection of saline
{1 ml/kg, i.p.), each week or in alternate week during
haloperidol withdrawal. Oral activity of these rats
remained at an elevated level, similar to that observed
before haloperidol withdrawal. Each point represents the
mean (± S.E.M.) number of oral movements (n»S-9),
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Effects of DA Receptor Antagonists on Spontaneous Oral
Activity of Haloperidol-Withdrawn n6-0HDA-Lesioned Rats
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Fig,14. Effects of DA receptor antagonists on spontaneous
oral activity of n6-0HDA-lesioned rats after haloperidol
withdrawal. Oral activity of nfi-OHDA-lesioned rats was
observed 10 min after vehicle administration (saline, l
ml/kg, i.p.) with or without pretreatment with a DA
receptor antagonists SCH 23390 HCl (1.0 mg/kg, i.p, lh),
spiperone HCl (0.08 mg/kg, i.p., lh) or metoclopramide HCl
(5.0 mg/kg i.p., lh). Bars represent mean (± S.E.M.) number
of oral movements (n**7-9) . These DA antagonists did not
attenuate the spontaneous oral activity of haloperidolwithdrawn n6-OHDA-lesioned rats (£>>0.05).
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Effects of 5-HT Receptor Antagonists on Spontaneous Oral
Activity of Haloperidol-Withdrawn n6-0HDA-lesioned Rats
I

| Saline

i

P indolol

■
K etanserin

Metoclopramide

Fig.15. Effects of 5-HT receptor antagonists on spontaneous
oral activity of n6-OHDA-lesioned rats after haloperidol
withdrawal. Oral activity of n6-OHDA-lesioned rats was
observed 10 min after vehicle administration (saline, 1
ml/kg, i.p.) with or without pretreatment with the 5-HT
antagonists pindolol (3.0 mg/kg, i.p., lh), ketanserin
tartrate (5.0 mg/kg, i.p., lh) or metoclopramide HCl (5.0
mg/kg, i.p., lh). Bars represent mean (± S.E.M.) number of
oral movements (n»S-9). These 5-HT receptor antagonists did
not attenuate the spontaneous oral activity of haloperidolwithdrawn nS-OHDA-lesioned rats (P>0.05).
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E f f e c t o f S copolam ine a n d Muscimol o n •
S p o n t a n e o u s Oral A ctivity o f H aloperidol-W ithdraw n
N e o n a ta l 6 -O H D A -L esio n ed R a t s
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Fig.16. Effects of scopolamine and muscimol on spontaneous
oral activity of n6-0HDA-lesioned rats after haloperidol
withdrawal. Oral activity of n6-OHDA-lesioned rats was
observed 10 min after vehicle administration (saline! l
ml/kg, i.p.) with or without pretreatment with scopolamine
HCl (0.1 mg/kg, i.p., lh) or muscimol (3.0 mg/kg, i.p., lh),
Bars represent mean (± S.E.M.) number of oral movements
(n»6-9).
*: P<0.05 vs. the oral activity after vehicle stimulation
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mRNA Levels of D2L, D2S and 5-HT2C Receptors
in Rat Striatum after Long-Term Haloperidol Treatment
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fig. 17. Messenger RNA levels of DA DaL, DJS and 5-HTac
receptors in the striatum of intact and neonatal 6-OHDAlesioned rats after long-term haloperidol treatment. mRNA
levels were determined by reverse transcriptase polymerase
chain reaction (RT-PCR). Each bar represents the
mean(±S.E.M.) number of relative mRNA levels expressed as
the percentage of fi-actin mRNA (n-6).
+: PcO.OS when compared to the same receptor subtype of
other groups

Chapter 4

Discussion
i

Due to the difficulty in obtaining human tissues for
investigation and the fact that available patients have
usually received complex therapeutic regimens, a direct
neurochemical basis underlying TD is difficult to be derived
from TD patients (Casey, 1987).

Therefore, animal models

play a significant -role in attempting to determine the
pathophysiological basis of TD.

Growing numbers of

investigations have sought to develope animal models for TD
{Crossman, 1987; waddington, 1990).

However, diversity, or

even conflicting results, especially the time of occurrence,
duration and persistence of spontaneous oral dyskinesias,
exist in the current animal models of TD.

It is important

to established an animal model that can reproduce the
phenomenology of TD patients and thereby.give rise to
evidence related to the etiological alterations of TD
(Waddington, 1990).
All primate models of TD were developed by long-term
treatment with neuroleptics such as haloperidol (Gunne and
Barany, 197G; Gunne et al., 1984) or fluphenazine (Kovacic
and Domino, 1984;

Gunne et al., 1984).

Under the treatment

by haloperidol (1-10 mg per kg, haloperidol decanoate, 3week interval) or fluphenazine (4-10 mg per kg, fluphenazine
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decanoate, 3-week interval) for a period of 1 to 3 years,
Gunne and associates reported similar symptoms to those of
TD observed in Cebus apella monkeys.

The motor defects

occured during treatment and persisted in the dyskinetic
monkeys for 1 to 6 years after cessation of neuroleptics
(Gunne and Barany, 1976,*

Gunne et al., 1984).

Kovacic and

Domino (1984) reported that bi-weekly treatment with
fluphenazine (0.1-3.2 mg/kg, IM) for 1 year did not produce
symptoms resembling TD in Cebus apella monkey until a few
months after the cessation of fluphenazine treatment.
During the period of fluphenazine treatment, all monkeys
displayed abnormal movements corresponding to the early
appearing extrapyramidal symptoms of neuroleptic-treated
patients.

These abnormal movements were prevented and

attenuated by the anticholinergic drug benztropine (0.2-0.6
mg/kg, IM). The distinct advantage of models developed in
primates over those in sub-primates is that primate models
exhibit a physical dyskinesia that is readily recognized.
Nevertheless, primates react to chronic neuroleptic
treatments in some aspects in a different way from humans.
The acute motor abnormality of monkeys to chronic
neuroleptic treatment and the alleviation of these acute
reactions by anticholinergic drugs stands in contrast to
what has been observed in TD patients (Crossman, 1987).
These have led to a criticism of the validity of primate
models of TD.

In addition, the high cost of primates also
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limits the availability of these animals for investigation.
Most studies of TD animal models have been carried out
in rodents, almost exclusively in rats (for review, see
Waddington, 1990).

All of the current TD animal models were

produced by long-term administration of neuroleptics such as
haloperidol, fluphenazine, trifluoperazine and
metoclopramine to intact rats.

The duration of drug

treatment ranges from 1.5 months to 13 months with durations
of withdrawal up to 5 months.

There were marked

inconsistencies among the rats models developed by
comparable treatments.

Some studies reported late-onset

oral movement (Ellison and See, 1989) whereas others
reported early emergence of similar movement (Rupniak et
al., 1985a) or even lack of any drug effect (Levy and
Ellison, 1987),

There were also conflicting results

concerning whether the altered oral activity can persist in
rats, a phenomenon that is found in TD patients.

Although

it has been reported that oral activity was able to persist
for up to 2.5 months in trifluoperazine-treated rats
(Waddington et al., 1983),

many other studies reported a

gradual diminution of oral activity during 2.5 to 5 months
of drug-withdrawal (Mithani et al., 1987; Gunne and
Haggstrom, 1983; Gunne et al., 1982).

It is difficult to

draw firm evidence toward the pathophysiology basis of TD
from current animal models because of the diversity in
outcomes of the present models.

Therefore, an improved TD
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animal model which can appropriately reproduce the
phenomenology and pathophysiology changes in human is
urgently needed (Waddington, 1990; Huang and Kostrzewa,
1994b).
The drugs being administered and the subjects receiving
such treatment are two major factors in the development of a
TD animal model (Waddington, 1990).

Since neuroleptics

induce abnormal oral activity in rodents, it is likely that
rodents and humans response to these drugs in a similar
manner.

Therefore, it appears to be appropriate to

administer neuroleptics to rats when developing a TD animal
model.

However, TD occurs when neuroleptics are given to

those human who have already had neuropsychiatric disorders
rather than to healthy people.

Therefore, intact rats may

not be appropriate subjects for animal models of TD.

Some

factors other than chronic neuroleptic treatment, perhaps
some extent of central nervous system damage, may
contribute to the emergence of TD syndromes in either TD
patients or rats.

In fact, more and more evidence suggests

that central dysfunction contributes to the vulnerability of
TD (Kane et al., 1985; Owens, 1985; Waddington et al., 1989;
Waddington, 1990).

There are closer associations between

abnormal orofacial dyskinesias and central dysfunctions
(such as produced by frontal cortex damage). It was also
proposed that TD is the result of loss of a discrete
subpopulation of striatal efferent neurons (probably
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striatonigral) which release GABA as their transmitter
(Fibiger and Lloyd, 1984).

It seemed to us that oral

dyskinesias are more likely to occur when rats with
endogenous or exogenous central dysfunctions, are under the
influence of chronic neuroleptic treatment.

Therefore, rats

with selective central DA neuronal destruction may serve as
a butter substrate as an animal model for neurolepticinduced tardive dysikinesias.
It is well known that n6-OHDA treatment produces
supersensitization of DA receptors in rats.

In n6-OHDA-

lesioned rats, doses of L-dihydroxyphenylalanine (L-DOPA),
SKF 38393 and A77636 [(1R,3S)-3-(1'-adamantyl)-1aminomethyl-3-4-dihydro-5,6-dihydroxy-1H-2-benzopyran)] that
have little effect on intact rats, produce great changes in
stereotyped, locomotor or oral activities in n6-OHDAlesioned rats (Breese et al., 1984, 1985a, 1985b; Hamdi and
Kostrzewa, 1991; Huang and Kostrzewa, 1994a; Kostrzewa,
1993, 1995; Kostrzewa and Brus, 1991).

Serotonin 5-HTj

receptor-mediated oral activity is also enhanced in these
rats {Gong and Kostrzewa, 1991).

In both the earlier DA

receptor supersensitization hypothesis (Klawans and Hitri,
1978; Chiu et al., 1981; Crossman, 1987) and the current
multi-neurotransmitter hypothesis of TD (Waddington, 1990),
the DA neuronal system is considered to be a major element.
Because chronic haloperidol treatment and neonatal 6-OHDA
treatment each sensitize DA receptors in rats, we believed
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that chronic neuroleptic-treated n6-OHDA-lesioned rats would
represent an improved TD animal model.

This provided the

basis of our study.
Neonatal 6-OHDA treatment markedly decreases the
striatal content of DA {Breese and Traylor, 1971,1972;
Breese et al., 1984) and elevates 5-HT content (Breese et
al., 1984; Stachowiak et al., 1984).

The findings of our

study are in agreement with those reports (table 3).

There

is >96% reduction of DA and HVA as well as 89% reduction of
DOFAC in the caudal striata of the n6-0HDA-lesioned rats,
regardless of whether rats were treated with haloperidol.
The concentrations of HVA and DOPAC in striatum are slightly
but significantly reduced in intact rats treated by long
term haloperidol (table 3).

In agreement with the earlier

report that HVA concentration and tyrosine hydroxylase (THJ
activity are significantly decreased by chronic (2 mg/kg/day
for 21 days) haloperidol treatment, reductions in the levels
of TH activity, DOPAC and HVA concentrations suggest a
reduced turnover of DA (Rastogi et al., 1982).

Rastogi and

associates (1982) did not find any change in the level of DA
in striatum in their haloperidol-treated rats, whereas DA
level in caudal striata of our haloperidol-treated rats was
significantly reduced.

This may due to the differences in

the length of treatment duration.

Meanwhile, as expected,

the striatal concentration of 5-HT and 5-HIAA were
significantly elevated by n6-OHDA treatment.

The unaltered
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levels of NE in the striatum indicate that selective
depletion of DA system with n6-0HDA treatment was wellachieved by desipramine pretreatment of rats (table 3).
In the present study the incidence of spontaneous oral
activity in intact and n6-0HDA-lesioned rats remained at
stable and low levels throughout the entire duration of the
study.

A neonatal 6-OHDA-lesioned per se did not cause a

significant increase in spontaneous oral activity (Fig.2;
Fig.3 1st, 2nd, 5th, 6th, 9th and 10th bars). The dose of
haloperidol (1.5 mg/kg/day) used in this study has been
shown to produce a plasma haloperidol level equivalent to
that observed in TD patients (Tamminga et al., 1990).

A

disproportionate increase of spontaneous oral activity
following chronic haloperidol treatment was found in rats
lesioned as adults with 6-OHDA (Gunne et al., 1982).

There

were no early emergence of any form of abnormal behavior in
our rats during haloperidol treatment.

However, after 15

weeks of haloperidol treatment the level of oral activity in
both intact and 6-OHDA-lesioned rats was markedly increased,
when compared to the respective base lines of oral activity.
Chronic haloperidol treatment produced a greater effect in
n6-0HDA rats vs. intact rats (Fig.2). In the present study,
when tested during the 12th, 36th and 38th weeks of
haloperidol treatment, the oral activity of n6-OHDA rats was
markedly elevated by the DA Dt receptor agonist SKF 38393
and 5-HT2 receptor agonist m-CPP (Figs. 4-7).

These

findings are in agreement with many others (Gong and
Kostrzewa, 1991; Kostrzewa and Gong, 1991; Huang and
Kostrzewa, 1994a) and indicate that there is a
supersensitization of DA D, and 5-HT, receptors that are
involved in oral response in n6-OHDA-lesioned rats.

If the

process of DA receptor supersensitivity partly accounts for
increased oral activity in TD patients (Chiu et al., 1981;
Klawans and Hitri, 1978; Crossman, 1987), the effects
produced by chronic haloperidol treatment could be either
additive or synergistic with the receptor sensitization
produced by a neonatal 6-OHDA lesion.

This could account

for the 2-fold higher oral activity in n6-0HDA-lesioned rats
vs. intact rats receiving haloperidol (Fig.2 and Fig.3).
The elevated level of oral activity that was induced by
chronic haloperidol treatment persisted unabated in n6-0HDAlesioned rats during the 8 months after haloperidol
withdrawal (Fig.13).

This is the longest withdrawal period

that has ever been described in neuroleptic-treated rats.
Considering the life span of rats, the persistence of
enhanced oral activity in these rats seems to represent a
permanent effect, akin to the oral dyskinesia accompanying
TD in humans.

It has been observed that increased oral

activity persists in about 65% of TD patients, long after
the cessation of neuroleptic treatment.

The greater the

duration of neuroleptic treatment, the more likely is the
abnormal oral activity to persist after neuroleptic

withdrawal (Jeste and Wyatt, 1982a/ Kane and Smithe, 1982}.
The long-live spontaneous oral dyskinesias of our rats
contrast with the rapid or gradual decay of this behavior in
intact rats that were withdrawn from haloperidol.

In 3

different strains of rats that received chronic haloperidol
in tap water at the same daily dose as in the present study
{1.5 mg/kg/day) there was a rapid decay in the frequency of
spontaneous oral activity during the first 2 weeks after
haloperidol withdrawal, to a level about half of that during
the haloperidol phase {Tamminga et al., 1990).

In a similar

experiment in which haloperidol was administered in tap
water for 300 days, there was also a rapid decay in
spontaneous oral activity of rats in the first month after
haloperidol withdrawal {Gunne et al., 1986).

Mithani et al.

(1987) reported that a similar decay in spontaneous oral
activity occurred in rats 2-8 weeks following withdrawal
from haloperidol- decanoate implants.

The interval following

haloperidol withdrawal is an opportune one for testing drugs
for their potential to attenuate oral dyskinetic behavior.
There was no decrement in spontaneous oral activity in the
lesioned rats following haloperidol withdrawal, indicating
that there is a stable baseline for testing the ability of
drugs to attenuate spontaneous oral activity.

Although

numerous trials have been carried for drug testing,
presently no drug have been proven to be both safe and
effective for TD treatment.

In rats the DA Dt receptor

antagonist SCH 23390 (0.01-0.25mg/kg) and DA Da receptor
antagonist sulpiride (4-100 mg/kg) reduced vacuous chewing
movements in a dose-dependent manner (Levin et al., 1989).
In monkeys that were withdrawn from chronic haloperidol
treatment for 1.5 years, chronic SCH 23390 (9 weeks)
treatment did not change the baseline of oral dyskinesia,
whereas raclopride (3 weeks) increased the oral activity of
these monkeys (Lublin et al., 1993).

The acute effect of

SCH 23390 on the oral dyskinesias of these monkeys was
biphasic.

That is, SCH 23390 increased oral activity of

these monkeys at a low dose (0,02 mg/kg) and reduced their
oral activity at a high dose (0.2 mg/kg). Raclopride had no
effect on oral activity of these monkeys (Peacock et al.,
1990).

Therefore, the effectiveness of DA receptor

antagonists on oral dyskinesias is unresolved.

In the

present study, the effect of SCH 23390 on oral activity was
tested before and after the cessation of haloperidol
treatment.

SCH 23390 (1.0 mg/kg) significantly attenuated

the oral activity of haloperidol-treated rats before
haloperidol withdrawal (Fig.8, 5th bar vs. 6th bar, P<0,05;
7th bar vs. 8th bar, P<0.01) but had no effect after
haloperidol withdrawal (Fig.14, 1st and 2nd bars).

The DA

Da receptor antagonists spiperone and metoclopramine had no
effect on oral dyskinesias after haloperidol withdrawal.
These results may relate to the view that an imbalance of Da
and Dj receptor sensitivity in favor of Da receptor is
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associated with oral dyskinesia (Peacock.et al., 1990).
The involvement of 5-HT systems in the behavioral
regulation was described almost 2 decays ago.

One of 'the

earliest reports regarding 5-H and behavior was that a
distinctive and highly reproducible motor syndrome was
elicited by 5-H precursors [L-5-hydroxytryptophan (5-HTP)
and L-tryptophan] (Jacobs, 1976).

Patterned motor

activities such as chewing, biting and licking behaviors are
associated with 5-H in adult animals (Jacob and Fornal,
1993;

Wallis, 1994) . Specifically, 5-Hax and 5-Hac

receptors are linked to the initiation of motor pattern
(Cazalets et al., 1992).

It was proposed that the major

function of 5-H neurons in the central nervous system is to
initiate and modulate motor outputs and to inhibit sensory
information processing.

These functions can be attenuated

when 5-HT systems are inhibited.

Therefore, central 5-H

systems are important for maintaining continuous output in
motor systems (Jacob and Fornal, 1993; Wallis, 1994) . It is
also known that 5-H systems, particularly 5-Hac receptors,
play important roles in regulating oral activity in rats
(Gong et al., 1992; Gong and Kostrzewa, 1992; Brus et al.,
1994) . Atypical neuroleptics have higher affinity to 5-H
receptors and produce much less extrapyramidal side effects
(such as TD) as compared to classical neuroleptics.
Therefore, while DA Da receptor blockade may be essential
for the treatment of psychosis, blockade of 5-HT receptors
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may reduce the incidence of extrapyramidal side effects.

It

is also quite possible that atypical neuroleptics modulate
DA function via 5-HT3 receptors (Meltzer and Nash, 1991).
5-HT3 receptor antagonists have been suggested as novel
neuroleptics with fewer side effects (Leysen et al., 1993).
Presently, in support with our previous findings (Gong
et al., 1992),

we find that the 5-HTiC receptor antagonist

mianserin attenuates both m-CPP- and SKF 38393-induced oral
activity in rats before haloperidol withdrawal {Fig.9),
After haloperidol withdrawal, the 5-HTlA/1B receptor
antagonist pidolol, 5-HTs receptor antagonist ketanserin and
5-HTj receptor antagonist metoclopramine fail to attenuate
spontaneous oral activity of the haloperidol-withdrawn rats
(Fig.15).

We had previously found that disruption of 5-HT

fibers by neonatal 5,7-DHT (5,7-dihydroxytryptamine)
treatment attenuates SKF 38393- and pilocarpine-induced oral
activity in n6-0HDA-lesioned rats.

It was thereby proposed

that multiple sites of interactions involvng 5-HT fibers and
5-HT receptors, take place between 5-HT and DA systems in
the brain.

Drugs acting on 5-HT receptors may be beneficial

in preventing or attenuating oral dyskinesias in TD patients
(Brus et al., 1994).
The involvement of central cholinergic systems are also
known to be involved in regulating oral activity in animals
(Rupniak et al., i.983, 1985a, 1985b; Salamone et al., 1990;
Kostrzewa and Neely, 1993).

However, the role of

cholinergic drugs on TD is still unclear,

in animals, acute

or co-administration of anticholinergic drug scopolamine
were found to decrease (Rupniak et al., 1983, 1985a;
Salamone et al., 1990; Steinpreis et al., 1993) or have no
effect (Stoessel et al., 1989) on oral activity induced by
chronic neuroleptic treatment.

Clinically it was found that

cholinomimetics are much more effective than cholinolytics
in reducing the severity of dyskinetic movements of TD.

In

many cases anticholinergic drugs aggravate TD symptoms
(Jeste and Wyatt, 1982a; Casey, 1987; Klawans and Rubovits,
1974).

It is generally agreed that cholinolytics alleviate

the early emergence of oral dystonias, while cholinomimetics
improve the symptoms of late-onset oral dyskinesias (Klawans
and Rubovits, 1974; waddington, 1990).

The response to

scopolamine has been used as one criterion to assess
cholinergic involvement in animal models of TD (Klawans and
Rubovits, 1974; Rupniak et al., 1983; Casey, 1987).

With

this in mind, we tested the effects of scopolamine on the
oral activity of our rats.

Scopolamine significantly

attenuated the elevated oral activity of haloperidol-treated
rats during the phase of haloperidol treatment (Fig. 12) but
had no effect during the phase after haloperidol was
withdrawn as a treatment (Fig.16).

The different responses

of oral activity to scopolamine and SCH 23390 before and
after haloperidol withdrawal indicate that different
neuronal interactions exist before and after the withdrawal
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□£ haloperidol. It is also possible that at the time when
the effect of scopolamine was tested during the haloperidol
treatment phase, the nature of oral activity of the rats was
more closely related to dystonia, and that the oral activity
after haloperidol withdrawal might more closely represent
TD.
Data from human and animal studies reveal that GABA
agonists such as muscimol and progabide are effective in
diminishing oral dyskinesias.

GABA levels in cerebrospinal

fluid (CSF) were found to be significantly decreased in TD
patients (Tamminga et al., 1979).

When administered to

neuroleptic-treated and neuroleptic-free TD patients,
muscimol at an oral dose of 5 to 9 mg consistently
attenuated involuntary oral movements

and improved TD

symptoms (Tamminga et al., 1979; Cassady et al., 1992).
Acute challenge and co-administration of progabide with
neuroleptics markedly reduced neuroleptic-induced oral
dyskinesias (Mithani et al., 1987; Kaneda et al., 1992).
Intrastriatal injection of muscimol (25 and 50 ng/0.2pg)
demonstrated that GABAergic inhibition of apomorphine
(0.2mg/kg, i.v .)-induced oral movement is regionally
specific.

Muscimol injected into the ventral striatum, but

not the dorsal striatum significantly inhibited oral
movement induced by apomorphine (KiKuchi de Beltran et al.,
1993).

Although it is difficult to separate the

antidyskinetic effects of GABA agonists from their sedative

and muscle relaxant effects and there is still no convincing
evidence to suggest that GABA agonists exert a specific
antidyskinetic effect (Jeste and Wyatt, 1982a), the
involvement of impaired GABAergic mechanisms in TD have been
widely accepted (Mithani et al., 1987; Cassady et al.,
1992).

In the present study, the GABA agonist muscimol, at

a dose of 3.0 kg/mg, significantly attenuated
during and after haloperidol treatment.

oral activity

In contrast,

bicuculline, a GABA receptor antagonist, does not have any
effect on the oral activity of haloperidol-treated rats
(Fig.10; Fig.11 and Fig.16).
Other neuronal systems such as opioid (Cancela et al.,
1988; Patrick et al., 1993) and neurokinin systems (Liminga,
1993) have been reported to be involved in the regulation of
oral activity.

With this in mind we tested a variety of

agents acting at different neuronal systems.

As listed in

table l, no significant effect on oral activity was found
with adrenergic receptor antagonists phenoxybenzamine (a),
phentolamine (a) and propranolol (S), or histamine receptor
antagonists cyproheptadine (HJ and ranitidine (Ha), or NMDA
(N-methyl-D-asparate) receptor antagonist (ketamine),
adenosine receptor antagonist (theophylline), opioid
receptor antagonist (naloxone) and agonist (morphine). The
NMDA receptor antagonist MK-801 significant reduced the oral
activity of the rats.

However, severe sedation and

immobility were also observed in these rats.

This may mask
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the effect of MK-801 on oral activity.

Therefore, it is

unlikely that these systems had a prominent role in
regulating oral activity of rats.
Chronic treatment with neuroleptics was shown to cause
a reversible increase in the B,w for DA Da receptors in rat
striatum {Duncan et al., 1987; Marin and Chase, 1993;
Laruelle, et al., 1992).

Clow et al. (1980) reported an

increased Bnax and Kd for DA Da receptors in rat striatum and
mesolimbic area after chronic trifluoperazine treatment,
The increased Bnax and Ka persisted for 3 months and 2 weeks
respectively after neuroleptic withdrawal.

Dewey and

Fibiger {1983) similarly reported that the elevated BBMt for
DA D3 receptors induced by chronic neuroleptic treatment,
returned to the control level 6 weeks after cessation of
neuroleptic.

Chronic neuroleptic treatment also increased

DA D3 density in rat caudate putamen {Jiang et al., 1990;
See et al., 1989).

The increase of D, receptor density in

rat striatum and caudate putamen was dissociated from DA
agonist-induced behavioral supersensitivity
Chase, 1993; Jiang et al., 1990).

{Marin and

There are conflicting

reports regarding neuroleptic-induced alterations in the
for DA Da receptors in other parts of brain.

Rupniak et al.

(1985b) found that DA Da receptors in nucleus accumbens
(mesolimbic system) are no longer blocked after 3-6 months
of neuroleptic treatment.

However, Laruelle and associates

found similar changes of Da receptor binding parameters in
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both rat striatum and nucleus accumbens (Laruelle et al.,
1992) . Neonatal 6-OHDA treatment (bilateral icv, 50 fig each
side)

at 3 days after birth was reported to increase

[JH]raclopride binding to the substantia nigra, all parts of
the caudal striatum and most parts of rostral striatum
(Radja et al,, 1993).

In contrast, intrastriatal injection

of 6-OHDA (4, 6 or 20 fig, each side) at 0 to 2 days after
birth did not cause significant changes in DA Da receptor
binding characteristics in rat striatum.

The lack of change

of DA Da receptors may be due to the absence of DA Da
receptors in the striatum at the time in ontogeny when rats
were lesioned (Neal and Joyce, 1992; Neal-Beliveau and
Joyce, 1993).

Duncan and colleagues (1987) reported that 15

days of chronic haloperidol treatment caused a significant
increase in the

for DA Da receptors in nucleus accumbens

of intact and adult 6-OHDA-lesioned rats but not in n6-OHDAlesioned rats.

In the striatum, this treatment also led to

a significant increase of Bw
lesioned rats.

in intact and adult 6-OHDA-

However, changes in the B„* for DA Da

receptors in the striatum of n6-0HDA-lesioned rats was not
determined in their study (Duncan et al., 1987).

In our

study (table 2), in agreement with the previous findings, DA
Da receptor density (B„J was significantly increased in the
intact rats receiving chronic haloperidol treatment while K4
was not significantly altered.

Neonatal 6-OHDA treatment

itself does not cause any change in DA Da binding

parameters.

However, there is a marked increase of the

for DA Da receptors in the striatum of n6-0HDA-lesioned rats
receiving haloperidol.

This finding conflicts with the

report in which the Bw

for DA Da receptors was found to be

unaltered in the nucleus accumbent of nG-OHDA-lesioned rats
after 15 days of haloperidol treatment (Duncan et al.,
1987} . The reason for this apparent discrepancy is unknown.
However, chronic neuroleptic-induced upregulation of Da
receptors in nucleus accumbens is transient. DA Da receptor
density increased temporary and returned to control level in
3-9 months after starting chronic neuroleptic treatment
(Clow et al., 1980; Rupniak et al., 1985b).

Eight months

after haloperidol withdrawal, the B^* for striatal DA Da
recepors in n6-OHDA-lesioned haloperidol-treated rats is at
control levels whereas the elevated spontaneous oral
activity still persists (table 2).

These results support

the view that behavioral changes in haloperidol-treated rats
is dissociated from changes in DA Da receptor number (Jiang
et al., 1990; Marin and Chase, 1993).
The molecular basis of DA Da receptor upregulation
after chronic haloperidol has been studied by many
investigators.

It is generally accepted that chronic

neuroleptic treatment increases the number of DA Da
receptors in the brain (Creese and Fraser, 1987).

In most

studies chronic haloperidol treatment increased striatal
mRNA of DA Da receptors (Bernard et al., 1991; Buckland et
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al., 1992; Jaber et al., 1994) although it has also been
reported that chronic neuroleptic treatment did not
influence the mRNA of DA D, receptors (Van Tol et al.,
1990) .
The DA Da receptor gene gives rise to two variants of
mRNA by alternate splicing.

These two variants of mRNA code

for two Da receptor isoforms termed DaL and D,s, with
sequences of 444 and 415 amino acids respectively.

DaL

protein has 29 more animo acids than Das in the third
intracellular loop of the receptor (Giros et al., 1989;
Monsma et al., 1989; Selbie et al., 1989; Martres et al.,
1992) . These two isoforms have the same ligand-binding
properties but it has been proposed that they may be coupled
differently to G proteins in signal transduction processes
(Monsma et al., 1989).

It was reported that 16 days (4mg/kg

per day, i.p.) or 32 days (1.5 mg/kg/injection, i.p. twice a
day) treatment of haloperidol significantly increased
striatal mRNA levels of both DaL and Dafl receptors (Fishburn
et al., 1994; Buckland et al., 1993).

Rogue and associates

reported an increase of striatal total Da and DaL receptor
mRNA levels after chronic haloperidol treatment (Rogue et
al., 1991).

In contrast, Srivastava et al.(1990) reported

no change in Da and Datl receptor mRNA levels of rat striatum
after chronic haloperidol treatment.

Similarly, both

striatal DaL and Da9 receptor mRNA levels were found
unaltered after chronic haloperidol (Matsunaga et al.,
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1990).

Therefore, the increase of mRNA levels may not be

critical for Da receptor up-regulation after long-term
haloperidol.

It is possible that post-transcriptional

mechanisms regulate the haloperidol-induced increase of Da
receptor numbers (Srivistava et al., 1990).

In our study,

in agreement with what was reported by Rogue and colleagues
(1991), we found that long-term haloperidol treatment
increased the mRNA levels of DJti receptors in both intact
and n6-0HDA-lesioned rats whereas Daa receptor mRNA levels
remained unchanged (Pig. 17}.

These findings imply that

different transcriptional mechanisms regulate the expression
of mRNA for two Da isoforms under the influence of chronic
haloperidol treatment.

The mechanism underlying this

regulation is yet to be determined.
A change in 5-HT receptor mRNAs after chronic
haloperidol treatment has not been reported.
interactions between

Because of the

central DA and 5-HT receptors,

especially 5-HTac receptors (Gong et al., 1992; Brus et al.,
1994), we determined the levels of 5-HTac receptor mRNA in
all rats after haloperidol treatment.

Levels of 5-HTac mRNA

were slightly but not significantly increased in both groups
of rats receiving haloperidol, as compared to the rats
without haloperidol treatment and the rats withdrawn from
haloperidol (Fig. 17).

Our findings suggest that the

interactions of DA and 5-HT systems in regulating oral
activity under chronic haloperidol treatment are not at the
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transcriptional level.

It is possible that the interactions

at post-transcriptional or receptor levels contribute to the
cross-talk of these two systems.
The present study utilized for the first time, chronic
haloperidol-treated n6-0HDA-lesioned rats as an animal model
of TD.

Long-term haloperidol treatment produces a greater

incidence of oral dyskinesias in n6-0HDA-lesioned rats vs.
intact rats.

Higher densities of DA D, receptors and

increased DA DJt, receptor mRNA levels in rostral striatum
were found in all rats that were treated by haloperidol.
Eight months after discontinuing haloperidol, the elevated
D, receptor densities and D3L receptor mRNA levels returned
to control levels whereas the oral dyskinesia still
persisted.

The dissociation of oral dyskinesia, Da receptor

density and mRNA levels indicates that Da receptor
upregulation is not important for the occurrence of oral
dyskinesias.

Instead, oral dyskinesias appear to be related

to an imbalance of multineuronal systems.

An advantage of

the present model of TD is the persistence of a stable
elevated baseline of oral activity after haloperidol
withdrawal, providing a means for dose-response testing and
even retesting of agents that have the potential to
attenuate dyskinetic oral activity.

Chapter 5
Summary

The finding of the present study are summarized as
following:
a.

Chronic haloperidol treatment produced a greater
incidence of oral activity on neonatal 6-OHDA-lesioned
rats vs. intact rats.

b.

The elevated oral activity in n-60HDA-lesioned rats
persisted for at least 8 months after withdrawal of
haloperidol treatment.

c.

The interval during haloperidol withdrawal is useful
for studying potential-useful drugs for treatment of
TD.

d.

Chronic haloperidol treatment significantly increased
dopamine DaL
receptor mRNA levels in rostral striatum of both intact
and neonatal 6-OHDA-lesioned rats.

e.

Chronic haloperidol treatment significantly increased
dopamine Da receptor density but not affinity in
rostral striatum of both intact and neonatal 6-0HDAlesioned rats.

d.

The increase of D3 density and D3t mRNA returned to
control level after 8 months of haloperidol
termination.
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